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Altered epidermal differentiation and the production of inflammatory cytokines and 
chemokines by epidermal cells are hallmarks of numerous skin diseases affecting over 
25% of the human population. Here I have identified Fra-2, an AP-1 transcription factor, as 
a key regulator of terminal epidermal differentiation and cytokine expression in 
keratinocytes. Mechanistically, Fra-2 binds and transcriptionally regulates gene promoters 
of epidermal differentiation genes, located within the Epidermal Differentiation Complex 
(EDC). EDC gene promoters are co-occupied by the transcriptional repressor Ezh2. Fra-2 
remains transcriptionally inactive in non-differentiated keratinocytes, where it was found 
mono- and dimethylated on lysine 104, and interacted with Ezh2. Upon keratinocyte 
differentiation, Fra-2 is C-terminally phosphorylated on serine 320 and threonine 322 by 
ERK1/2, leading to transcriptional activation. Thus, the induction of epidermal 
differentiation by Fra-2 is controlled by a dual mechanism involving Ezh2-dependent 
methylation and activation by ERK1/2-dependent phosphorylation. During skin 
morphogenesis in mice, epithelial-restricted, ectopic expression of Fra-2 induced EDC 
gene expression.  Moreover, in a papilloma-prone background, reduced tumor burden was 
observed due to precocious keratinocyte differentiation by Fra-2 expression. Importantly, 
loss of Fra-2 in suprabasal keratinocytes is sufficient to cause skin barrier defects due to 
reduced expression of differentiation genes. 
Besides impairing keratinocyte differentiation, loss of epidermal Fra-2 (Fra-2Δep) results in 
inflammation characterized by epidermal hyperplasia, infiltration of inflammatory cells into 
the dermis and epidermis and high serum cytokine levels. Additionally, Fra-2-deficient 
keratinocytes display increased p65/NF-κB activity and the concurrent removal of epithelial 
p65 partially attenuates the skin and systemic phenotype of Fra-2Δep mutants. These 
findings identify an important function of epidermal p65 in initiating inflammatory 
processes. Additionally, a cell autonomous but indirect regulation of Fra-2 on the 
expression of the cytokine TSLP by keratinocytes was uncovered.  
Interestingly, transplanting Fra-2Δep skin onto immune-compromised SCID mice gave rise 
to the formation of skin papillomas, suggesting a tumor protective role of the acute 
inflammatory response observed in Fra-2Δep skin. 
My data demonstrate a cell-autonomous function of Fra-2 in epithelial homeostasis by 
regulating keratinocyte differentiation, p65 activity and epithelial cytokine expression, 
which are causally involved in the development of inflammatory skin diseases and skin 
tumors.
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Las alteraciones en la diferenciación epidérmica y la producción de citoquinas 
inflamatorias y quimiocinas por las células epidérmicas son señas de identidad de 
numerosas enfermedades de la piel que afectan a más del 25% de la población humana. 
Aquí he identificado Fra-2, un factor de transcripción AP-1, como un regulador clave de la 
diferenciación epidérmica y la expresión de citoquinas en los queratinocitos. 
Mecanísticamente, Fra-2 se une y regula transcripcionalmente promotores de genes de 
diferenciación epidérmica ubicados dentro del Complejo de Diferenciación Epidérmica 
(EDC del inglés Epidermal Differentiation Complex). Los promotores de los genes EDC 
son co-ocupados por el represor transcripcional Ezh2. Fra-2 permanece 
transcripcionalmente inactiva en los queratinocitos no diferenciados, donde se encontró 
mono y dimetilado en la lisina 104, e interactuando con Ezh2. Tras la diferenciación de los 
queratinocitos, Fra-2 es fosforilado en el extremo C-terminal, en la serina 320 y la treonina 
322, por ERK1/2, lo cual conduce a su activación transcripcional. Por lo tanto, la inducción 
de la diferenciación epidérmica por Fra-2 se controla mediante un doble mecanismo de 
metilación dependiente de Ezh2 y la activación por fosforilación dependiente de ERK1/2. 
Durante la morfogénesis de la piel en ratones, la expresión ectópica de Fra-2, restringida 
a células epiteliales, indujo la expresión de los genes EDC. Además, en ratones 
susceptibles a papilomas se observó una reducción de los tumores debido a una 
diferenciación precoz de queratinocitos por la sobreexpresión de Fra-2. Es importante 
destacar que la pérdida de Fra-2 en los queratinocitos suprabasales es suficiente para 
causar defectos de barrera de la piel debido a la reducción de la expresión de genes de 
diferenciación. 
Además de alterar la diferenciación de los queratinocitos, la pérdida de Fra-2 (Fra-2Δep) en 
la epidermis resulta en una inflamación que se caracteriza por hiperplasia epidérmica, 
infiltración de células inflamatorias en la dermis y la epidermis y niveles de citoquinas 
séricas elevadas. Además, los queratinocitos deficientes en Fra-2 muestran una mayor 
actividad de p65/NF-kB y la eliminación simultánea de p65 epitelial atenúa parcialmente el 
fenotipo de la piel y sistémico de los mutantes Fra-2Δep. Estos hallazgos identifican una 
función importante de p65 epidérmico en la iniciación de los procesos inflamatorios. 
Además, se pudo constatar una regulación autónoma pero indirecta de Fra-2 sobre la 
expresión de la citoquina TSLP por los queratinocitos. 
Sorprendentemente, el trasplante de piel Fra-2Δep en ratones inmunocomprometidos 
(SCID) dio lugar a la formación de papilomas en la piel, lo que sugiere un papel protector 
frente a tumores de la respuesta inflamatoria aguda observada en la piel Fra-2Δep. 
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Mis datos demuestran una función autónoma de Fra-2 en la homeostasis epitelial 
mediante la regulación de la diferenciación de queratinocitos, la actividad de p65 y la 
expresión de citoquinas epiteliales que están implicadas causalmente en el desarrollo de 
enfermedades inflamatorias de la piel y tumores de piel. 
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AD   Atopic Dermatitis 
AK   Actinic Keratosis 
AP-1   Activator Protein 1 
AP-2   Activating Protein 2 
Arnt   Aryl hydrocarbon receptor nuclear translocator 
ATF   Activating Transcription Factor 
BCC   Basal cell carcinoma 
Bcl-2   B-cell lymphoma 2 
BM   basement membrane 
bp   base pair 
bZIP   basic leucine zipper 
C/EBP   CCAAT/enhancer binding protein 
Ca2+   calcium 
CBP   CREB-Binding Protein 
CD4   cluster of differentiation 4 
CD45   cluster of differentiation 45 
CD8   cluster of differentiation 8 
CE   cornified envelope 
ChIP   chromatin immunoprecipitation 
coIP   co-immunoprecipitation 
DC   dendritic cell 
DETC   dendritic epidermal T cell 
DKO   double knock-out 
DMBA   7,12-Dimethylbenz[a]anthracene 
DNA    deoxyribonucleic acid 
E17.5   embryonic day 17.5 
ECM   extracellular matrix 
EDC   Epidermal Differentiation Complex 
ELISA   Enzyme Linked Immunosorbent Assay 
EGFR   Epidermal Growth Factor Receptor 
ERK   Extracellular-Signal-Regulated Kinase 
FBS   fetal bovine serum 
FGF   fibroblast growth factor 
Flg   Filaggrin 
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Fra-2/p65∆ep  knock-out of Fra-2 and p65 in all epidermal cells 
Fra-2∆ep  knock-out of Fra-2 in all epidermal cells 
Fra-2∆sb  knock-out of Fra-2 in suprabasal cells 
Fra-2Ep-tetOFF  ectopic expression of Fra-2 in epithelial cells 
Fra-2 K104F  Fra-2 mutant with substitution of lysine 104 to phenylalanine 
Fra-2 S320A/T322A Fra-2 mutant with substitution of serine 320 and threonine 322 to 
alanine 
GEMM   genetically engineered mouse model 
GOF   gain of function 
Grhl3   grainyhead-like 3 
H&E   hematoxylin and eosin 
H2   histone 2 
H3   histone 3 
H3K27me3  histone 3 lysine 27 trimethylation 
H3K4me3  histone 3 lysine 4 trimethylation 
HF   hair follicle 
HIF1α   hypoxia-inducible factor 1 alpha 
IF   immunofluorescence 
IgE   Immunglobulin E 
IHC   immunohistochemistry 
IL-13   interleukin 13 
IL-17   interleukin 17 
IL-1ß   interleukin 1 beta 
IL-1α   interleukin 1 alpha 
IL-4   interleukin 4 
IL-6   interleukin 6 
IP   immunoprecipitation 
IκB nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor 
JNK   c-Jun N-terminal kinase 
K14-HPV transgenic mice that expresses human papillomavirus in keratin 14 
expressing tissues 
K5-SOS-F transgenic mice that express a dominant form of Son of Sevenless 
(SOS-F) in keratin 5 expressing tissues 
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KGF   keratinocyte growth factor 
KLF4   Kruppel-like factor 4 
LB   lamellar bodies 
LCE   late cornified envelope gene 
Lcn2   Lipocalin-2 
LIF   leukemia inhibitory factor 
LOF   loss of function 
LOH   loss of heterozygosity 
Lor   Loricrin 
MAF   musculoaponeurotic fibrosarcoma 
MAP kinase  mitogen-activated protein kinase 
MS   Mass spectrometry 
mKC   mouse keratinocyte 
mRNA   messenger ribonucleic acid 
NF-κB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NOD scid gamma immunodeficient mice that lack mature T cells, B cells, and natural 
killer cells 
OCT   Optimal Cutting Temperature 
o/n   over night 
P2   postnatal day 2  
P6   postnatal day 6 
PcG   Polycomb Group 
Pen/Strep  Penicillin/Streptomycin 
PFA   paraformaldehyde 
PKC   protein kinase C 
PRC   Polycomb Repressive Complex 
PTCH   Patched 
PTM   posttranslational modification 
RHD   Rel homology domain 
RT   room temperature 
S100A8  S100 calcium binding protein A8 
S100A9  S100 calcium binding protein A9 
SCC   squamous cell carcinoma 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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SHH   sonic hedgehog 
SMO   smoothened 
STAT3   signal transducer and activator of transcription 3 
TACE   TNF alpha converting enzyme 
Tchhl1   trichohyalin-like 1 
TEWL   transepidermal water loss 
TF   transcription factor 
Th cell   T helper cell 
Timp3   tissue inhibitor of metalloproteinase 3 
TLR   Toll-like receptor 
TNF   tumor necrosis factor 
TPA   12-O-Tetradecanoylphorbol-13-acetate 
TRE   TPA responsive element 
TrxG   Trithorax Group 
TSLP   Thymic Stromal Lymphopoietin 
WB   Western blot 
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1. TRANSCRIPTIONAL MECHANISMS 
One fundamental goal of biological sciences is to understand how different cell fates are 
acquired during development and how cellular identity is maintained in adulthood. The set 
of genes that are transcribed largely defines the cell. Mammals contain hundreds of cell 
types, and most of these have yet to be studied with respect to the set of transcripts they 
contain. The gene expression programs that regulate somatic tissue development are 
controlled by coordinated interactions of tissue specific transcription factors, cofactors, and 
chromatin regulators (Figure 1-I) (Young, 2011). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-I. General transcriptional machinary at active gene promoters. Adopted from Young, 
2011. 
1.1. Transcription factors 
In mammals, transcription factors (TF) make up the largest single class of proteins 
encoded in the genome, representing approximately 10% of all protein coding genes 
(Levine and Tjian, 2003). TFs integrate extracellular signals and function as gatekeepers 
between the cell surface and the nucleus. They recognize specific DNA sequences and 
either promote or prevent the recruitment of RNA polymerase II, the enzyme converting 
genetic information from DNA to messenger RNA (mRNA), a process termed transcription 
(Jacob and Monod, 1961). Many of these transcriptional regulators cluster into large 
families defined by highly homologous DNA-binding domains that have the capacity to 
bind highly similar DNA sequences. A small number of key TFs dominate the control of 
gene expression programs. They function in a temporally and spatially appropriate pattern 
at correct levels for normal tissue development (Cole and Young, 2008).  
The activities of TFs themselves are often regulated through one or more posttranslational 
modifications (PTMs). PTMs constitute covalent chemical changes - such as 
phosphorylation, methylation, acetylation, sumoylation or glycosylation - to specific 
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residues in the protein sequence. These PTMs orchestrate every activity of a TF from 
subcellular localization to protein-protein interactions, sequence-specific DNA binding, 
transcriptional regulatory activity, and protein stability (Filtz et al., 2014).  
1.1.1. Transcription factor phosphorylation 
To activate or repress gene expression, TFs must be located in the nucleus, bind DNA, 
and interact with the basal transcription apparatus. Most commonly, this is regulated by 
reversible phosphorylation. Phosphorylation is the addition of a phosphate group to a 
serine, threonine or tyrosine residue of a protein (Gonzalez et al., 1989; Hunter and Karin, 
1992). Phosphorylation of a TF by several different kinases is a simple mechanism that 
allows different signals to converge at the same factor. For numerous TFs, 
phosphorylation increases protein stability, fosters interaction with transcriptional 
cofactors, promotes nuclear translocation and thereby increases its transcriptional activity 
(Gonzalez et al., 1989; Hill and Treisman, 1995; Treisman, 1994). However, there are 
other examples where phosphorylation decreases stability, inhibits the nuclear 
translocation or the DNA binding affinity of a TF (Cowley and Graves, 2000; Okamura et 
al., 2000). Phosphorylation of TFs is a regulatory mechanism that is both rapid and readily 
reversible. Furthermore, as a TF can be targeted by many protein kinases and 
phosphatases, phosphorylation can effectively integrate information carried by multiple 
signal transduction pathways, thus providing opportunities for further versatility and 
flexibility in gene regulation (Calkhoven and Ab, 1996; Chinenov and Kerppola, 2001; 
Karin and Hunter, 1995). 
1.1.2. Transcription factor methylation 
Methylation is the addition of a methyl group to a lysine or arginine residue of a protein. 
Once bound to DNA, p53, NFκB, STAT3, GATA4 and several other TFs are reversibly 
methylated on lysine residues by enzymes that also modify histones. These modifications 
profoundly affect the activity of TFs at these promoters, altering their stability, 
transactivation potency, and affinity for DNA, and thus affecting the strength and duration 
of gene expression. For example, methylation of GATA4 attenuates its transcriptional 
activity by reducing its interaction with a transcriptional cofactor (Chuikov et al., 2004; He 
et al., 2012; Kim et al., 2013; Levy et al., 2011).  
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1.1.3. AP-1 transcription factors 
The AP-1 (activator protein 1) TF is a dimeric complex that comprises members of the Jun 
(c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra-1 and Fra-2), ATF (activating transcription 
factor) and MAF (musculoaponeurotic fibrosarcoma) protein families. The AP-1 complex 
can therefore form many different combinations of hetero- and homo-dimers, and this 
combination determines the promoter binding affinity and the genes that are regulated by 
AP-1 (Chinenov and Kerppola, 2001; Vogt, 2002). AP-1 proteins are termed basic leucine-
zipper (bZIP) proteins because they dimerize through a leucine-zipper motif and contain a 
basic domain for DNA binding. AP-1 TFs recognize the consensus sequence TGAC/GTCA 
also termed the TPA-responsive element (TRE), because it is strongly induced by the 
tumor promoter 12-O-tetra-decanoylphorbol-13-acetate (TPA) (Figure 2A-I) (Angel and 
Karin, 1991). 
The regulation of AP-1 activity is complex and occurs at different levels, including dimer 
composition, transcriptional and post-translational events, and interactions with co-
activators or -repressors (Bakiri et al., 2002; Chang and Karin, 2001; van Dam and 
Castellazzi, 2001). The DNA binding of the AP-1 complex to the TRE sequence is rapidly 
induced by growth factors, cytokines and oncogenes (Angel and Karin, 1991). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-I. AP-1 transcription factor. A. Schematic representation of an AP-dimer bound to a 
TRE DNA element. B. Transcriptional and post-translational modifications of AP-1. Adapted 
from Eferl and Wagner, 2003. 
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AP-1 proteins are phosphorylated and activated by mitogen activated protein (MAP) 
kinases including Jun N-terminal kinase (JNK), p38 and Extracellular Signal-Regulated 
Kinase (ERK) (Eferl and Wagner, 2003). ERKs phosphorylate c-Fos, Fra-1 and Fra-2, 
thereby enhancing their DNA binding activity, as they heterodimerize with Jun proteins 
(Chang and Karin, 2001). JNKs phosphorylate c-Jun and less efficiently JunD, but they do 
not phosphorylate JunB (Figure 2B-I) (Kallunki et al., 1996). 
AP-1 TFs control distinct biological processes including cellular proliferation, 
differentiation, oncogenic transformation, apoptosis and inflammation (Eferl and Wagner, 
2003; Zenz et al., 2008). 
 
1.1.4. NF-κB transcription factors 
In mammals, the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
TF family consists of five proteins, p65 (RelA), RelB, c-Rel, p105/p50 (NF-κB1), and 
p100/p52 (NF-κB2) that associate with each other to form distinct transcriptionally active 
homo- and heterodimeric complexes. They all share a conserved 300 amino acid N-
terminal Rel homology domain (RHD). Sequences within the RHD are required for 
dimerization, DNA binding, interaction with inhibitor of kappa B (IκB), as well as nuclear 
translocation (Baldwin, 1996). 
NF-κB signaling plays critical roles in inflammation, immunity, cell proliferation, 
differentiation, and survival (Barnes and Karin, 1997; DiDonato et al., 2012). Inducible NF-
κB activation depends on phosphorylation-induced proteosomal degradation of IκB 
proteins, which retain inactive NF-κB dimers in the cytosol in unstimulated cells. The 
majority of the diverse signaling pathways that lead to NF-κB activation converge on the 
IκB kinase (IKK) complex, which is responsible for IκB phosphorylation and is essential for 
signal transduction to NF-κB. Additional regulation of NF-κB activity is achieved through 
various PTMs of the core components, such as phosphorylation or acetylation of p65, 
which increase its transcriptional activity (Ghosh and Karin, 2002).  
Over the past years, inflammation has emerged as a hallmark of tumor growth and 
progression. Of various signaling cascades involved in inflammatory processes, the NF‐κB 
pathway has received extensive attention as a key mediator providing a link between 
inflammation and tumorigenesis (DiDonato et al., 2012; Karin, 2006). 
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1.2. Transcriptional cofactors 
TFs typically bind cofactors, which are protein complexes that contribute to activation (co-
activators) and repression (co-repressors) but do not have DNA binding properties of their 
own (Roeder, 1998).  
Most TFs are thought to contribute to transcription initiation by recruiting co-activators 
such as mediator, p300 or its homolog CREB-binding protein (CBP), which in turn bind 
and control the activity of the transcription initiation apparatus (Conaway et al., 2005; Malik 
and Roeder, 2005). p300/CBP is one of the most potent and versatile acetyltransferases. 
p300/CBP acetylates and regulates the activity of various transcription-related proteins 
besides histones, by transferring an acetyl group from acetyl-coenzyme A to the ɛ-amino 
group of specific lysine side chains, it regulates the activity of a multitude of proteins 
(Brownell and Allis, 1996; Gu and Roeder, 1997; Janknecht and Hunter, 1996). 
1.3. Chromatin regulators 
Eukaryotic genomes are packaged into nucleosomes, which provide a means to compact 
the genome and to influence gene expression (Kornberg and Thomas, 1974; Olins and 
Olins, 1974). Early and recent studies revealed that gene expression can be influenced by 
histone-modifying enzymes that acetylate, methylate, ubiquitinate and otherwise 
chemically modify nucleosomes. These modifications provide interaction surfaces for 
protein complexes that contribute to transcriptional control. Enzymes that remove these 
modifications are also typically present at active genes, producing a highly dynamic 
process of chromatin modification as RNA polymerase is recruited (Bannister and 
Kouzarides; Brownell et al., 1996; Campos and Reinberg, 2009; Gardner et al., 2011). 
Chromatin regulators are generally recruited to genes by DNA binding transcription 
factors, the transcription apparatus, or specific RNA species (Guenther and Young, 2010; 
Roeder, 2005; Surface et al., 2010).  
1.3.1. Histone-modifiying enzymes 
The chromatin regulators with the most important impact on somatic tissue development 
are histone-modifying enzymes, a group of epigenetic regulators required for the earliest 
stages of embryonic lineage commitment (Sauvageau and Sauvageau, 2010). These 
include the Polycomb group (PcG) protein complexes, which are antagonized by the 
Trithorax group (TrxG) proteins. The corresponding genes were first identified in 
Drosophila melanogaster as repressors and activators of Hox genes (Bracken and Helin, 
2009; Ringrose and Paro, 2004; Schuettengruber et al., 2007). TrxG proteins catalyze 
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trimetylation of histone H3 on lysine 4 (H3K4me3) at the promoters of active genes and 
facilitate maintenance of active gene states during development (Jenuwein and Allis, 
2001). PcG proteins associate to form two major complexes, which are Polycomb 
Repressive Complex  (PRC) 1 and 2. The mammalian PRC1 complex consists of four 
main subunits: one of the Cbx proteins (Cbx2-4-6-7-8), Ring1 (Ring1A/B), PHC (PHC1-3) 
and PCGF (PCGF1-6) (Levine et al., 2002). On the other hand, the PRC2 complex is 
formed by three core subunits Ezh1/Ezh2, Eed and Suz12 (Cao et al., 2002). The catalytic 
function of PRC2 requires methyltransferase activities of either Ezh1 or Ezh2, with Ezh2 
being more catalytically active (Margueron et al., 2008).  
 
 
 
 
 
 
 
 
 
 
Figure 3-I. Polycomb-mediated gene silencing. Adopted from Choi and Friso, 2010. 
 
PRC2 is recruited to chromatin and Ezh1/2 mediate the trimethylation of histone H3 on 
lysine 27 (H3K27me3). This histone mark presents a docking site for PRC1, which actively 
participates in gene silencing by monoubiquitination of H2A at lysine 119 and subsequent 
chromatin compaction (Figure 3-I) (Francis et al., 2004; Min et al., 2003; Simon and 
Kingston, 2009). H3K27me3 is found at genes that are silent but poised for activation at 
some later stage of development and differentiation (Orkin and Hochedlinger, 2011; 
Young, 2011). 
Whether H3K27 methylation is the only way by which Ezh2/PRC2 controls transcription 
remains unclear. Since Ezh2 has other substrates beyond histone H3, it was proposed 
that Ezh2 might be involved in regulating tissue homeostasis by controlling the activity of 
these non-histone substrates, such as some TFs (He et al., 2012; Kim et al., 2013; Lee et 
al., 2012; Xu et al., 2012). 
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2. THE SKIN 
The skin is emerging as an ideal model system to characterize the functional roles of 
transcriptional mechanisms that orchestrate organogenesis and adult tissue homeostasis. 
Due to its ability to regenerate throughout adulthood and the availability of excellent 
genetic tools, in vivo systems using mouse models offer a number of advantages to study 
gene functions during skin development and disease.  
The skin is the body’s largest organ in surface and weight. Mammalian skin comprises a 
stratified epithelium - the epidermis, a multilayered sheet of keratinocytes - and an 
underlying connective tissue, the dermis (Figure 4-I) (Frye and Benitah, 2012). 
Interactions between dermal cells and keratinocytes play a crucial role in the regulation of 
tissue morphogenesis, homeostasis and repair (Beck and Blanpain, 2012). The skin 
primarily serves as a protective barrier and prevents dehydration, mechanical trauma, 
microbial insults, and it is essential for temperature regulation, secretion and sensation. 
Complex interactions of different cell types found within the skin, orchestrated by 
coordinated transcriptional mechanisms, ensure these vital functions (Fuchs, 2009; Fuchs 
and Horsley, 2008; Watt, 2014).  
2.1. The Dermis 
The dermis is the fibrous connective tissue between the epidermis and the subcutaneous 
fat. Mesenchymal fibroblasts are the major cell type in the dermis and deposit the collagen 
and elastic fibres of the extracellular matrix (ECM) (Driskell et al., 2013; McLafferty et al., 
2012). The dermis also contains adipocytes, blood and lymph vessels, nerve endings, hair 
follicles and glands. Immune cells, such as macrophages, mast cells, B- and T-
lymphocytes and dendritic cells also populate the dermis (Gebhardt et al., 2011). 
Specialized resident immune cells found mainly in the dermis, including dendritic cells and 
γδ T cells, protect against invading pathogens (Watt and Fujiwara, 2011) (Figure 4-I). 
2.2. The Epidermis 
Due to its constant exposure to the outer surface of the body, skin epithelia must 
rejuvenate constantly to maintain its barrier function, ensure long-term homeostasis and 
regenerate damaged areas. To fulfill these essential functions, the epidermis generates an 
elaborate array of supportive appendages, including hair follicles, sebaceous glands, 
sweat glands, and nails. Since terminally differentiated cells are continuously shed from 
the body surface, new cells have to replace the ones that are lost. In addition, hair follicles 
undergo re-occurring cycles of growth and regression. Epidermal homeostasis, hair 
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regeneration, and wound repair are maintained by several reservoirs of self-renewing stem 
cells located at distinct anatomical locations within the skin, that upon specific stimuli 
become activated, multiply and differentiate according to the needs of their particular 
compartment. The balance between proliferation and differentiation of keratinocytes is 
tightly regulated and the disruption of this balance causes several pathological conditions 
including inflammation and tumorigenesis (Blanpain and Fuchs, 2009, 2014; Fuchs, 2009; 
Hsu and Fuchs, 2012; Hsu et al., 2014). 
Besides keratinocytes, three other cell types reside within the epidermis: Melanocytes, 
Langerhans cells and Merkel cells. Melanocytes are located in the lower part of the 
epidermis and synthesize melanin, the pigment that gives skin its natural color (Haass and 
Herlyn, 2005). Langerhans cells are dendritic cells (antigen-presenting immune cell) of the 
epidermis, also called dendritic epidermal T cells (DETC). They are present in all layers of 
the epidermis, but are most prominent in the spinous layer, where they take up and 
process microbial antigens to become fully functional (Romani et al., 2012) (Figure 4-I). 
Merkel cells are oval receptor cells that have synaptic contacts with somatosensory 
neurons. These cells are involved in the sensation of light touch (Boulais et al., 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-I. Compartments/cell types of the skin. Adapted from Wagner et al., 2010. 
Abbreviations: DC, dendritic cell; DETC, dendritic epidermal T cell; NK, natural killer cell. 
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2.2.1. Epidermal morphogenesis 
In mice the program of epidermal morphogenesis begins at approximately embryonic day 
(E) 9.5 with a single layer of ectodermal cells that will undergo epidermal stratification at 
E14.5, resulting in the formation of a functional epidermal barrier at E18.5 (Blanpain and 
Fuchs, 2009; Koster and Roop, 2007). 
Keratinocytes found within the innermost (basal) layer of this stratified epithelium rest upon 
a basement membrane (BM), which is rich in extra-cellular matrix proteins and growth 
factors and separates the epidermis from the underlying dermis. Basal cells, which 
express high levels of keratin 5 (K5), K14 and basal integrins, retain a population of 
progenitors that retain their proliferative potential and rely upon BM and mesenchymal 
stimuli to remain proliferative. Upon detachment from the BM, epidermal keratinocytes 
progress through several stages of differentiation that form three consecutive suprabasal 
layers: the spinous layer (stratum spinosum), the granular layer (stratum granulosum) and 
the outermost cornified layer (stratum corneum) (Figure I4) (Blanpain and Fuchs, 2006; 
Blanpain et al., 2007). 
2.2.1.1. Basal-to-spinous transition  
Each stage of differentiation is characterized by morphological and complex biochemical 
changes corresponding to the expression of different structural proteins. The major 
structural change at the basal-to-spinous transition, as proliferating basal keratinocytes 
become suprabasally mitotically inactive, is the switch from K5/K14 intermediate filaments 
in the basal layer to K1/K10 in the suprabasal layer. Spinous keratinocytes are attached 
together through desmosomes, which transmit physical forces onto K1 and K10 and build 
a scaffold for upper epidermal layers (Fuchs and Green, 1980; Koster and Roop, 2007). 
2.2.1.2. Terminal differentiation 
Upon subsequent migration, cells enter the granular layer, where the most abundant 
cornified envelope protein Loricrin (Lor) is expressed (Blanpain and Fuchs, 2009). 
Profilaggrin is also expressed at this stage of differentiation, and soon afterwards, it is 
proteolytically processed to generate Filaggrin (Flg), a protein that bundles keratin 
filaments into indestructible cables (Aho et al., 2012). Other terminal epidermal 
differentiation proteins are Trichohyalin-Like 1 (Tchhl1), and the Late Cornified Envelope 
proteins (LCEs). They are deposited on keratin intermediate filaments and increase 
mechanical strength (Fuchs and Horsley, 2008). 
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A multitude of genes necessary for terminal epidermal differentiation and cornification are 
found within the Epidermal Differentiation Complex (EDC), a gene-rich region of human 
chromosome 1q21, which corresponds to mouse chromosome 3. Interestingly, besides 
structural proteins required for skin barrier formation, this locus encodes chemoattractants 
such as S100 proteins, which are secreted by stressed keratinocytes and act on a 
multitude of immune cells (de Guzman Strong et al., 2010; Fessing et al., 2011; Segre, 
2006). 
2.2.1.3. Formation of the cornified envelope (CE) and skin barrier 
Acquired just before birth and at the last stage of epidermal differentiation, the skin's 
barrier creates a surface seal essential for protecting animals against microbial infections 
and dehydration. As granular cells transit to the stratum corneum, their metabolic activity 
ceases, and an influx of calcium (Ca2+) results in an activation of transglutaminases, which 
crosslink EDC gene products to generate the cornified envelope (CE) (Eckert et al., 2005). 
Concomitantly, lipids (free fatty acids, ceramides, cholesterol) first accumulate in lamellar 
bodies (LB), which are organelles that develop from the Golgi complex. LBs later fuse with 
the cell membrane to secrete their material into the extracellular environment. Secreted 
ceramides are covalently bound to the outside of the cornified envelope and assemble on 
this scaffold as multilayered lipid lamellae, thereby waterproofing the skin surface (Ishida-
Yamamoto et al., 2004; Kalinin et al., 2001). Eventually, keratinocytes in the stratum 
corneum undergo apoptosis and are released from the surface of the epidermis (Blanpain 
and Fuchs, 2009). The program of epidermal differentiation is maintained throughout the 
lifespan of an organism and is regulated at several levels by numerous signaling pathways 
and transcription factors, as well as epigenetically. The functionality of the skin barrier in 
mice can be assessed by dye penetration assays – evaluation of the outside-in barrier - 
and by measuring the transepidermal water loss (TEWL), to measure the functionality of 
the inside-out barrier (Blanpain and Fuchs, 2009; Botchkarev et al., 2012; Eckert et al., 
2011; Frye and Benitah, 2012; Truong and Khavari, 2007; Zhang et al., 2012). 
2.2.2. Ca2+ induced in vitro epidermal differentiation 
Mammalian epidermis displays a characteristic Ca2+ gradient, with highest levels in the 
granular and lowest levels in the basal layer, which is important for both permeability 
barrier homeostasis and epidermal differentiation (Menon et al., 1985). Much has been 
learned about Ca2+-regulated differentiation from in vitro studies. Keratinocytes in low Ca2+ 
concentrations (0.05mM) proliferate but fail to differentiate. When switched to Ca2+ 
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concentrations above 0.1mM, the differentiation process is initiated. Keratinocytes rapidly 
undergo morphologic changes with the development of cell–cell contacts that are critical 
for the differentiation process (Figure 5-I). The sustained increase in intracellular Ca2+ 
results in the activation of PKC (Protein kinase C) and upon activation of down-stream 
kinases and TFs, the sequential expression of K1 and K10, Lor and Flg. Therefore, “Ca2+ 
switch” experiments with undifferentiated, proliferating keratinocytes can be used to mimic 
epidermal differentiation in vitro to study transcriptional mechanisms (Bikle et al., 2013; 
Yuspa et al., 1989).  
 
 
 
 
 
 
 
 
 
Figure 5-I. Ca2+ gradient in vivo and in vitro. Adopted from Nakamura and Fukami, 2009.  
2.2.3. Transcriptional regulators in epidermal differentiation 
2.2.3.1. TF functions in the basal-to-suprabasal transition 
At the transcriptional level, the basal-to-spinous switch is controlled by p63 and the 
canonical Notch signaling pathway. The down-regulation of the epidermal master regulator 
p63, which is expressed in basal epidermal cells, presents a central event for the basal-to-
spinous transition to happen (Dotto, 2009; Koster et al., 2004). The canonical Notch 
pathway is also crucial during the early steps of basal cell commitment to spinous cells. 
Ligands of Notch reside in the basal layer, and receptors for Notch are expressed 
suprabasally by spinous cells. Exceeding Notch activity promotes the fate of K1/K10-
expressing spinous cells, while insufficient Notch signaling results in a diminution of this 
differentiated state (Blanpain et al., 2006; Rangarajan et al., 2001). Among Notch’s target 
genes are the transcriptional repressor Hes1 and C/EBPs, which transcriptionally regulate 
many differentiation-specific genes, including K1 and K10. Additionally, Notch collaborates 
with AP-2 TFs to fully initiate spinous cell differentiation (Moriyama et al., 2008; Wang et 
al., 2008). 
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2.2.3.2. TF functions in terminal differentiation 
Despite the clustering of EDC genes, a local master regulator has not been identified. 
Thus, it appears that EDC genes are controlled by a pool of ubiquitously expressed TFs. 
They include Klf4, GATA3, Grainyhead-like 3 (Grhl3), and Aryl hydrocarbon receptor 
nuclear translocator (Arnt). These factors are crucial for terminal epidermal differentiation, 
and their ablation in mice is lethal due to reduced expression of EDC genes and 
consequently skin barrier defects (de Guzman Strong et al., 2006; Geng et al., 2006; 
Jaubert et al., 2003; Patel et al., 2006; Segre et al., 1999; Ting et al., 2005).  
2.2.3.3. Epigenetic regulation of epidermal differentiation 
The involvement of polycomb group proteins Bmi1, Cbx4, Ezh2 and Jarid2, as well as 
additional epigenetic modifiers in establishing tissue-specific differentiation programs in 
the epidermis has been demonstrated recently (Aarenstrup et al., 2008; Driskell et al., 
2012; Ezhkova et al., 2011; Ezhkova et al., 2009; Fessing et al., 2011; Kashiwagi et al., 
2007; Luis et al., 2011; Mejetta et al., 2011). 
In the epidermis, loss of Ezh2 impaired proliferation and induced premature differentiation 
of keratinocytes during embryonic development. Mechanistically, it was proposed that 
EDC gene expression was due to increased AP-1 TF activity in the absence of the 
repressive H3K27me3 mark (Ezhkova et al., 2009). Interestingly, despite the complete 
absence of H3K27me3 marks in Ezh1/2 null keratinocytes, only few genes bound by 
PRC2 were actually up-regulated in the absence of Ezh1/2, suggesting that the repression 
of differentiation genes is not only mediated by trimethylation of H3 at K27 (Ezhkova et al., 
2011).  
2.3. Dermal and epidermal cross-talk 
Transcriptional mechanisms in the skin are also influenced by interactions between 
mesenchymal, hematopoietic and epithelial cells, which are responsible for complex 
events such as tissue development, homeostasis, repair as well as disease (Werner and 
Smola, 2001). In mammalian skin, multiple types of resident cells are required to create a 
functional tissue and support tissue homeostasis and regeneration. Pioneering studies of 
Rheinwald and Green demonstrated that epidermal keratinocytes depend on the presence 
of fibroblasts for efficient growth in tissue culture (Rheinwald and Green, 1975). Later on, a 
fibroblast-derived growth factor (FGF), termed Keratinocyte Growth Factor (KGF), which 
strongly simulated the proliferation of keratinocytes, was identified (Finch et al., 1989). 
Disrupting the expression of these factors in fibroblasts severely affected the proliferation 
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and differentiation of overlying keratinocytes (Szabowski et al., 2000).  
During development, the epidermal-dermal interactions coordinate hair follicle (HF) 
formation. The first recognizable feature of HF morphogenesis is the formation of the 
placode, an epidermal invagination that occurs in the epidermis at the site of an underlying 
dermal condensation of mesenchymal cells (Fuchs, 2007; Hardy, 1992). Intraepidermal 
Wnt signaling is necessary and sufficient for HF initiation (Fu and Hsu, 2013). 
Furthermore, two recent studies unravel important functions of intradermal adipocytes and 
macrophages in follicular stem cell activation and HF fate, underlining the importance of 
epidermal-dermal interaction in HF cycling (Castellana et al., 2014; Festa et al., 2011). 
2.4. Skin diseases 
Deregulation of the described gene expression programs during epidermal stratification as 
well as deregulation of the dermal and epidermal crosstalk can cause a broad range of 
skin diseases. The frequent incidence of human disorders characterized by aberrant 
epidermal differentiation and consequently skin barrier defects, such as Atopic Dermatitis 
(AD) and Psoriasis, and epidermal cancers, that affect more than 25% of the general 
population, highlight the importance of coordinated transcriptional programs in 
keratinocytes (Blanpain et al., 2007; de Cid et al., 2009; Deady et al., 2014; Rogers et al.; 
Smith and Barker, 2006). Keratinocytes are a source of stress-associated cytokines and 
chemokines produced in response to mechanical insults, cutaneous pathogens or 
oncogenic transformation (Mullins et al., 2009; Wollina et al., 2004). Because they 
constitute the majority of cells in the epidermis, the skin’s primary barrier, they are the first 
cell type to be exposed to harmful insults and respond rapidly by secreting soluble factors 
and increasing their proliferative potential in order to restore tissue damage (Gause et al., 
2013; Hong et al., 2001; Nagao et al., 2012).  
Since the skin is a multifaceted organ composed of several cell types, the etiology of skin 
diseases involves a complex crosstalk among epidermal keratinocytes, dermal fibroblasts, 
endothelial cells and the immune system. The production of cytokines, chemokines and 
growth factors is thought to mediate these diseases (Wagner et al., 2010).  
2.4.1. Inflammatory skin diseases 
AD and psoriasis are the two most common chronic inflammatory skin diseases found in 
the general population characterized by dry and scaly skin (Holgate, 1999). Although both 
diseases are generally regarded as immune-mediated conditions, genetic studies have 
indicated the importance of abnormalities in epithelium-expressed genes as a primary 
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cause. Loss of function alleles of the skin barrier protein Flg were found to be a major 
predisposing factor for AD (Palmer et al., 2006) and a copy number polymorphism of a 
beta defensin gene cluster was associated with increased risk for psoriasis (Hollox et al., 
2008). The histological abnormalities of skin biopsies of patients with AD and psoriasis 
include excessive keratinocyte proliferation, expression of specific keratins, such as K6 
and K16 as well as impaired differentiation of epidermal keratinocytes. Disturbed 
keratinocyte differentiation results in a diminished thickness of the stratum granulosum of 
the epidermis and an irregular and thickened stratum corneum (hyperkeratosis) with 
retention of nuclei within corneocytes (parakeratosis). Chronic dermatitis, with infiltration of 
immune cells into the dermis and subcutaneous tissue, and abnormal development of 
blood vessels are also characteristic features of AD and psoriasis (Nedoszytko et al., 
2014). Even though lesional skin of both patients with AD and psoriasis is heavily 
infiltrated with activated T cells that produce inflammatory cytokines, the mechanisms for 
skin inflammation and the propensity for skin infections are quite different in the two 
diseases (Nomura et al., 2003a; Nomura et al., 2003b). The immune response in AD is Th 
(T helper cell) 2-mediated contributing to the high IgE levels as well as eosinophil and 
mast cell infiltration, characteristic of this condition (Leung, 2000). Additionally, the 
secretion of the cytokine Thymic Stromal Lymphopoietin (TSLP) by keratinocytes has 
been linked to AD (Ziegler and Artis, 2010). High Th2-cytokines, such as IL-4, and low 
levels of proinflammatory cytokines such as IFN-γ and TNF-α produced by AD skin might 
explain the increased susceptibility of AD patients to skin infections by microorganisms 
(Nomura et al., 2003b). 
In contrast, the immune response in psoriasis is Th1/Th17-mediated and associated with 
local neutrophil and macrophage infiltration (Di Cesare et al., 2009; Nickoloff, 2001). 
Psoriatic keratinocytes produce proinflammatory cytokines, such as IL-1β, IFN-γ and TNF-
α (Johnson-Huang et al., 2009) as well as antimicrobial β-defensins and neutrophil- 
chemoattractant S100 proteins (Lowes et al., 2007). 
In both inflammatory skin diseases, the production of these secreted factors by 
keratinocytes contribute to dendritic cell (DC) activation (Soumelis et al., 2002). Once 
activated, DCs migrate into skin-draining lymph nodes to present antigens to naïve CD4+ 
and CD8+ T cells and promote their differentiation into Th1/Th17 or Th2 cells. Attracted by 
keratinocyte-derived factors, inflammatory cells migrate into the skin via lymphatic and 
blood vessels (Johnson-Huang et al., 2009). 
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2.4.1.1. Treatment of inflammatory skin diseases 
A multitude of topical and systemic treatments, including glucocorticoids, retinoids, 
cyclosporin and ultraviolet irradiation have been used for the treatment of psoriasis and 
mild AD (Bieber, 2008; Wagner et al., 2010). In addition, biologic agents that target either 
general inflammatory pathways, such as the TNF pathway for psoriasis (Menter et al., 
2009), or distinct pathways of immune cell activation, such as antibodies or inhibitors that 
block IL-4, IL-13, IL-17 and IL-23, have become part of the therapeutic strategies for AD 
and psoriasis patients (Beck et al., 2014; Ratner, 2015; Yiu and Warren, 2015). Despite 
progress in the management of these diseases, patients with moderate to severe AD 
disease still poorly respond to treatment and psoriasis patients usually relapse (Beck et 
al., 2014). Therefore, it is necessary to develop both improved and novel curative 
strategies for the treatment of AD and psoriasis (Wagner et al., 2010).  
2.4.2. Skin cancer 
Skin cancer is the third most common human malignancy and its occurrence has been 
increasing rapidly over the past decades. An estimated number of 2-3 million non-
melanoma skin cancer patients and 132,000 patients of melanoma are counted every year 
(World health organization). 
Melanoma is the type of skin cancer that arises from melanocytes, melanin-producing cells 
located in the basal layer of the epidermis. It is the most dangerous type of skin cancer as 
it is the leading cause of death from skin disease (Tsao et al., 2012). 
Non-melanoma skin cancer comprises two major types of skin cancers, Basal and 
Squamous Cell Carinoma (BCC and SCC). Both tumors arise from keratinocytes, but are 
very different in morphology and in the underlying mechanisms (Colmont et al., 2012). 
2.4.2.1. Basal cell carcinoma (BCC) 
BCC is the most common and least dangerous form of skin cancer (Kasper et al., 2012).  
Several genes of the Sonic Hedgehog (SHH) signaling pathway are frequently mutated in 
BCCs. Approximately 90% of sporadic BCCs have identifiable mutations in at least one 
allele of PTCH1, and an additional 10% have activating mutations in the downstream 
effector protein smoothened (SMO), which renders SMO resistant to inhibition by PTCH1 
(Epstein, 2008). Several compounds targeting members of the SHH signaling pathway are 
currently used in clinical trials. Removal of tumors using surgery in less invasive BCCs as 
well as topical treatment with the Toll-like receptor (TLR) 7/8 agonists Resiquimod or 
Imiquimod are widely established (Kasper et al., 2012).  
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2.4.2.2. Cutaneous Squamous cell carcinoma (SCC) 
SCCs are the second most common type of human cancer with over 250,000 new cases 
annually in the USA and it is the second in incidence after BCC. It arises from 
keratinocytes of the epidermis and oral mucosa. Unlike BCCs, cutaneous SCCs are 
associated with substantial risk of metastasis and are notoriously resistant to conventional 
and targeted drug treatments. SCC typically manifests as a spectrum of progressively 
advanced malignancies, ranging from a precursor lesion like actinic keratosis (AK) to SCC 
in situ, invasive SCC and finally metastatic SCC (Ratushny et al., 2012)  
Similar to other cancers, SCCs exhibit impaired genomic stability that facilitates acquisition 
of new mutations. p53 is commonly mutated in dysplasic lesions. 40% of SCCs in situ 
harbor p53 mutations, indicating that p53 loss occurs prior to tumor invasion (Campbell et 
al., 1993; Pierceall et al., 1991b). Aberrant activation of Epidermal Growth Factor Receptor 
(EGFR) and Fyn, a Src-family tyrosine kinase, are found in human SCCs. Furthermore, 
amplification and activating mutations of the Ras oncogene have been described in SCCs 
(Pierceall et al., 1991a).  
Skin SCC has been extensively modeled by either making use of genetically modified 
mice, such as K14-HPV (Human Papilloma Virus) or K5-SOS-F mouse models (Arbeit et 
al., 1994; Sibilia et al., 2000) or by using a two-step chemical carcinogenesis protocol. In 
this protocol, mutations in H-Ras are induced by a single topical dose of a carcinogen, 
most commonly 7,12-dimethyl‐benz[a]anthracene (DMBA), applied on the back skin. 
Repeated topical applications of a tumor promoter, such as TPA give rise to benign 
neoplastic lesions, characterized by sustained hyperplasia (papillomas) and inflammation. 
A small percentage of these papillomas progress to malignant invasive SCCs. In these 
carcinomas, loss of heterozygosity (LOH) and mutations of p53 are frequent, similar to 
human SCC (Brown et al., 1986; Quintanilla et al., 1986).  
2.4.2.3. Tumor microenvironment in skin cancers 
The tumor microenvironment/stroma is composed of leukocytes, fibroblasts (cancer 
associated fibroblasts), endothelial cells, soluble factors (cytokines, chemokines, matrix 
metalloproteases, growth factors) and ECM (Hanahan and Weinberg, 2011). Interestingly, 
stroma shows many features of the skin wound healing response after tissue damage. In 
contrast to wounds, however, in cancers this process is chronically perturbed, resulting in 
uncontrolled cell proliferation, invasive growth and eventually metastasis (Dvorak, 1986; 
Schafer and Werner, 2008).  
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It is well established that inflammatory processes can both hinder and facilitate cancer by 
fostering infiltration of leukocytes and promoting stromal remodeling (Demaria et al., 
2010). In human skin, the development of AK lesions and in situ SCC is linked to chronic 
inflammation. These lesions can be effectively reversed by treatment with TLR agonists 
that trigger a potent acute inflammatory reaction, which results in tumor stasis/clearance 
within a few weeks (Ibrahim and Brown, 2009). Additionally, the risk of SCC is 
substantially increased in clinical conditions associated with chronic inflammation. 
However, not all types of inflammation increase the cancer risk as reflected by the 
surprising skin cancer resistance of psoriasis patients (Nestle et al., 2009). 
Interestingly, two recent studies highlight the importance of the keratinocyte-derived 
cytokine TSLP on inducing tumor protective inflammation by activating CD4+ and CD8+ T 
cells. Using mouse models of impaired Notch signaling in the skin, which develop 
epidermal barrier defects and AD-like skin inflammation, it was demonstrated that 
abrogation of T cell-mediated protection results in the accumulation of tumor-promoting 
CD11b+Gr1+ myeloid cells, which secrete Wnt ligands and thereby augment β-catenin 
signaling in the neighboring epithelium (Figure 6-I) (Demehri et al., 2012; Di Piazza et al., 
2012). 
 	  	  	  	  	  	  	  	  	  	  	  
 
Figure 6-I. TSLP protects from skin cancer by directly activating dermal T cells. Skin tumor 
formation upon blockade of TSLP. Tumors recruit Wnt-secreting protumorigenic CD11b+Gr1+ 
cells. The development of skin tumors is β-catenin dependent. Link: Skin barrier defects - 
epidermal TSLP secretion – skin cancer by Di Piazza et al., 2012. 
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Collectively, these studies underline the important functions of transcriptional regulators in 
epidermal differentiation and demonstrate that a perturbation in this process can result in 
tumor-protective skin inflammation controlled by a keratinocyte-derived cytokine, which 
acts on specific T cell subsets. Additionally, these studies reveal that different subsets of 
immune cells mediate the outcome of skin inflammation from tumor protective to tumor 
promoting. 
2.4.3. AP-1 functions in epidermal homeostasis and disease 
Deregulated AP-1 expression is found in skin biopsies of patients with 
inflammatory/proliferative skin diseases, such as psoriasis and epithelial cancers, such as 
SCCs (Briso et al., 2013; Eckert et al., 2013; Guinea-Viniegra et al., 2014; Guinea-Viniegra 
et al., 2012; Zenz et al., 2005). Interestingly, genome scans revealed AP-1 consensus 
binding sites throughout the EDC cluster (Ezhkova et al., 2009), suggesting regulatory 
functions of AP-1 TFs on these genes. 
The generation of genetically engineered mouse models (GEMMs) has provided important 
insights into the functions of Jun proteins as well as c-Fos in epidermal homeostasis, 
inflammation and cancer. More specifically, primary mouse keratinocytes proliferate poorly 
and show increased expression of early differentiation markers, such as K10 in the 
absence of c-Jun. Furthermore, the epidermal deletion of c-Jun in tumor-prone K5-SOS-F 
transgenic mice resulted in smaller papillomas, with reduced expression of EGFR 
(Epidermal Growth Factor Receptor) in basal keratinocytes (Zenz et al., 2003). Notably, 
mutant mice with epidermal-specific deletion of JunB develop a G-CSF-dependent 
inflammatory skin disease (Meixner et al., 2008). Additionally, an important function of 
skin-derived IL-17 on osteoblast differentiation has been characterized in this model 
(Uluçkan and Wagner, unpublished). Deletion of both JunB and c-Jun, in a constitutive or 
inducible manner, leads to perinatal death of newborn pups and to a psoriasis-like disease 
in adults, respectively, in which TNFα and the TIMP-3/TACE pathway as well as C3 and 
S100A8/A9 signaling play central roles (Guinea-Viniegra et al., 2009; Schonthaler et al., 
2014; Zenz et al., 2005). Recent results showed that c-Fos, which regulates keratinocyte 
differentiation under oncogenic stress conditions (Guinea-Viniegra et al., 2012), acts as a 
proto-oncogene in the skin and promotes the formation of SCC (Briso et al., 2013). In 
contrast, the functions of the Fos-related proteins Fra-1 and Fra-2 in the epidermis are still 
poorly understood. As c-Fos is only expressed in keratinocytes upon stress conditions, we 
speculate that Fra proteins heterodimerize with Jun proteins in keratinocytes to regulate 
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epidermal homeostasis. Here, the functions of Fra-2 in the epidermis were investigated. 
2.4.3.1. Fra-2 functions in physiology and disease 
Using gain and loss of function mouse models, our laboratory has previously unraveled 
important roles of Fra-2 in mesenchymal and hematopoietic cells. It was shown that Fra-2 
has essential functions in bone homeostasis as mice lacking Fra-2 display deficiencies in 
chondrocytes which resulted in less mineralized bone (Karreth et al., 2004). Furthermore, 
Fra-2 controls osteoclast survival and size through LIF/LIF-receptor signaling and hypoxia. 
Fra-2-deficient mice have giant osteoclasts and the expression of HIF-1α and Bcl-2 is 
increased (Bozec et al., 2008). More recent studies revealed an additional function of Fra-
2 as positive regulator of bone formation, since its deletion results in osteoblast 
differentiation defects, whereas over-expression of Fra-2 revealed an osteosclerotic 
phenotype (Bozec et al., 2010). In addition, mice lacking Fra-2 in osteoblasts exhibit 
increased body fat and glucose intolerance with increased adiponectin expression (Bozec 
et al., 2013). 
Notably, Fra-2 transgenic mice, ectopically expressing Fra-2 in various organs, develop 
generalized fibrosis with predominant manifestation in the lung and the liver (Eferl et al., 
2008). Recent data from our lab indicate that Fra-2 in mesenchymal cells of the lung and 
the liver might be relevant in fibrosis. 
In mouse skin, Fra-2 is expressed in all epidermal layers (Eckert et al., 2013). The Fos-
related protein is known to be an ERK 1/2 MAP kinase target (Eriksson and Leppa, 2002; 
Murakami et al., 1997) and the ERK 1/2 MAP kinase pathway is active during Ca2+ 
induced differentiation via PKCα (Schmidt et al., 2000; Seo et al., 2004). Therefore, the 
functions of Fra-2 during keratinocyte differentiation and skin homeostasis were 
investigated. 
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AP-1 transcription factors have important functions in skin development, inflammation and 
cancer. However, the functions of the Fos-related protein Fra-2, an important regulator of 
mesenchymal and hematopoietic cell fate, have not been studied in epithelial cells. 
The following objectives were addressed in this thesis: 
 
 
1.) Investigate the functions of Fra-2 during keratinocyte differentiation. More 
specifically, analyze the expression, post-translational modifications and identify novel 
interaction partners and target genes of Fra-2 in vitro during calcium-induced keratinocyte 
differentiation. 
 
2.) Generate epithelial-specific gain- and loss-of-function mouse models of Fra-2 to 
validate the expression of the identified target genes, and to uncover deregulated 
pathways that may interfere with epidermal homeostasis, affect inflammatory processes 
and eventually lead to skin cancer development.  
 
3.) Dissect the molecular mechanisms of how aberrant epidermal differentiation, skin 
inflammation and skin cancer formation are linked using these genetically engineered 
mouse models, skin transplantation models and primary keratinocyte cultures. 
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Los factores de transcripción AP-1 desempeñan funciones importantes en el desarrollo de 
la piel, los procesos inflamatorios y el cáncer. Sin embargo, las funciones de la proteína 
de la familia de Fos Fra-2, un importante regulador del destino final de células 
hematopoyéticas y mesenquimales, no se han estudiado en células epiteliales. Por lo 
tanto, se abordaron los siguientes objetivos en esta tesis: 
 
 
1.)  Investigar las funciones de Fra-2 durante la diferenciación de los queratinocitos. 
Más específicamente, analizar la expresión, las modificaciones post-traduccionales e 
identificar nuevas moléculas de interacción y genes diana de Fra-2, in vitro, durante la 
diferenciación de queratinocitos inducida por calcio. 
 
2.)  Generar modelos de ratón con ganancia o pérdida de función de Fra-2 
específicamente en células epiteliales para validar la expresión de los genes diana 
identificados, y para descubrir vías desreguladas que pueden interferir con la homeostasis 
epidérmica, afectar a los procesos inflamatorios y eventualmente resultar en el desarrollo 
de cáncer de piel. 
 
3.)  Diseccionar los mecanismos moleculares de cómo los procesos de diferenciación 
epidérmica aberrante, la inflamación de la piel y la aparición de cáncer de piel están 
vinculados utilizando estos modelos de ratones genéticamente modificados, modelos de 
trasplante de piel y cultivos de queratinocitos primarios. 
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1. MICE 
1.1. Study approval 
All experiments were performed in accordance with institutional policies and national and 
European guidelines. Mice were kept in the CNIO animal facility and all animal 
experiments were approved by the Animal Experimental Ethics Committee of the Instituto 
de Salud Carlos III (Madrid, Spain). 
1.2. Generation of Fra-2 and Fra-2/p65 loss-of-function mouse models 
To generate epithelial-specific Fra-2 loss-of-function (LOF) mutants and Fra-2/p65 double 
knock-out (DKO) mutants, the Cre-loxp system was used (Orban et al., 1992). 
Fra-2Δsb mice were generated by crossing mice carrying Fra-2 alleles flanked by loxP sites 
(Fra-2f/f) (Eferl et al., 2007) with mice expressing Cre recombinase under the control of the 
FoxN1 promoter (Soza-Ried et al., 2008). Fra-2Δep mice were generated by crossing Fra-
2f/f mice with mice expressing Cre recombinase under the control of the K5 promoter 
(Tarutani et al., 1997). Fra-2/p65Δep mice were generated by crossing Fra-2f/f mice and 
p65f/f mice (Algul et al., 2007) with mice expressing Cre recombinase under the control of 
the K5 promoter. Control (Cre negative mice), Fra-2Δsb mutants (Fra-2f/f; FoxN1 Cre+/T), 
Fra-2Δep mutants (Fra-2f/f; K5 Cre+/T) and Fra-2/p65Δep mutants (Fra-2f/f; p65f/f; K5 Cre+/T) 
were identified by genotyping PCR on tail biopsies using standard PCR conditions and the 
following primers (Table 1-M).  
Table 1-M 
Allele Name Primer Sequence (5’ – 3’) 
sense GAGGGAGTTGGGGATAGAGTGGTA 
Fra-2(f/+) 
antisense GGACAGCAGGTCAGGAGTAGATGA 
sense GAGGGAGTTGGGGATAGAGTGGTA 
Fra-2Δ 
antisense TGTACCGGACGCTTGTCATCTCAT 
sense GAGCGCATGCCTAGCACCAG 
p65(f/+) 
antisense GTGCACTGCATGCGTGCAG 
sense GTGCACTGCATGCGTGCAG 
p65Δ 
antisense ACTGAAGCGGCCAGGATG 
sense GCATTACCGGTCGATGCAACGAGTGATGAG 
Cre 
antisense GAGTGAACGAACCTGGTCGAAATCAGTGCG 
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1.3. Generation of Fra-2 gain-of-function mouse model 
To generate an epithelial-specific Fra-2 gain-of-function (GOF) mouse model with 
inducible expression of Fra-2, we made use of the Tretracycline-Controlled-Transcriptional 
Activation (tTA) method. This system permits the switchable expression of a specific gene 
upon the presence or absence of the tetracycline antibiotic or one of its derivatives such 
as doxycycline (Gossen and Bujard, 1992) 
Fra-2Ep-tetOFF mice were generated by crossing mice carrying a Flag-tagged Fra-2 cDNA 
knock-in controlled by a tetracycline operator, downstream of the col1a1 gene  (col Fra-
2+/KI) (Bozec et al., 2013) to mice expressing tTA from the K5 promoter (Diamond et al., 
2000). Control (col Fra-2+/KI; K5tTA+/+) and Fra-2Ep-tetOFF mutants (col Fra-2+/KI; K5tTA+/T) 
were identified by genotyping PCR on tail biopsies using standard PCR conditions and the 
following primer sequences (Table 2-M). 
Table 2-M 
Allele Name Primer Sequence (5’ – 3’) 
sense GCACAGCATTGCGGACATGC 
antisense 1 CCCTCCATGTGTGACCAAGG col Fra-2 
antisense 2 GCAGAAGCGCGGCCGTCTGG 
sense ATGCTACCATAGTCATATCGTCATGCATGCAT 
K5tTA 
antisense TATCGTCATGCATGCATATGCTACCATAGTCA 
 
Fra-2Ep-tetOFF SOS+ mice were generated by crossing Fra-2Ep-tetOFF mice to K5-SOS-F mice 
(EGFRwa/wa, K5 SOS+/T) (Sibilia et al., 2000). EGFRwa/wa and K5 SOS+/T genotypes were 
evaluated by macroscopic appearance and used to generate SOS+ (col Fra-2+/KI, K5tTA+/+, 
EGFRwa/+, SOS+/T) and Fra-2Ep-tetOFF SOS+ (col Fra-2+/KI, K5tTA+/T, EGFRwa/+, SOS+/T) mice. 
All mice generated were maintained in the absence of doxycycline so that transgene 
expression was turned on during embryonic development. 
1.4. Dye penetration assay 
Timed matings were set up, a positive vaginal plug in the early morning was considered as 
E0.5 and pregnant females were sacrifized at E17.5 to collect embryos. E17.5 embryos 
were rinsed once in PBS and once in 100% methanol, stained in 0.1% Toluidine blue for 
30 minutes at room temperature and washed in PBS before image capture. 
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1.5. Mouse to mouse skin grafts 
Back skin of Fra-2Δep and Co pups was dissected at postnatal day 2 (P2), cut longitudinally 
into two parts of equal size and grafted onto 4-8 week old Nod/SCID gamma mice by 
stitching with Premilene 6/0. Skin grafts were wrapped and hosts were treated with 
Ibuprofen for 24h after transplantation and antibiotics for 2 weeks after transplantation. 
Wrapping was changed one week after transplantation and removed two weeks after 
transplantation. The graft on the immuno-deficient mouse was followed over 4 weeks. 
2. HISTOLOGY  
2.1. Formalin-fixed paraffin-embedded tissue 
Back skins from embryos at embryonic day E17.5, back skins from pups at postnatal day 6 
(P6) and tails skins from 1-month old adult mice were fixed overnight (o/n) with buffered 
10% PFA at 4°C and embedded in paraffin. 3µm skin sections were cut. Hematoxylin and 
Eosin (H&E) and Immunohistochemistry (IHC) were performed as previously described 
(Zenz et al., 2005). Antigen retrieval was performed in sodium citrate (10mM, pH 6) in a 
pressure cooker, slides were blocked in PBS, 0.1% Triton X, 1%BSA, 1% donkey serum 
and washed in PBS, 0.1% Triton X. The following primary antibodies (Abs) were used for 
IHC: p-ERK1/2 (Thr202/Tyr204) (1:1000, #4370, Cell Signaling), Fra-2 (1:50, CNIO 
Monoclonal Antibody Unit), CD45 (1:200, BD Pharmingen 550539), Ki67 (1:200, Dako) 
and p65 (1:1000, Santa Cruz sc-372). Elite ABC kit (Vector Labs) secondary Abs were 
used and nuclei were counterstained with hematoxilin. Sections were analyzed by light 
microscopy (LeicaDM2500).  
2.2. Fresh frozen tissue 
Back skins from embryos at E17.5 and tail skins from adult mice were embedded in 
optimal cutting temperature (OCT) compound, snap frozen in dry ice and cut at 10µm. 
Immunofluorescence (IF) was performed as described previously (Perez-Moreno et al., 
2006). Tissues were fixed in 4% PFA, slides were blocked in PBS, 0.1% Triton X, 1%BSA, 
1% donkey serum, washed in PBS, 0.1% Triton X. Primary antibodies used for IF were: 
Fra-2 (1:50, CNIO Monoclonal Antibody Unit), K5 (1:1000, Covance), Filaggrin (1:1000, 
Covance), Loricrin (1:1000, Covance), Ki67 (1:200, Dako), Ezh2 (1:1000, #5246, Cell 
Signaling). Alexa Fluor secondary Abs conjugated to 488nm or 555nm emitting 
fluorophores (Invitrogen) were used. Sections were mounted with Mowiol + DAPI 
(Vectashield) and analysed by confocal microscopy. 
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3. MUTAGENESIS AND CLONING 
For the generation of Fra-2 methyl- and phospho-mutants, site-directed mutagenesis was 
carried out on Flag-tagged mouse Fra-2 cloned in pGEM7Zf vector using the QuikChange 
Lightening Site-directed Mutagenesis kit (Stratagene, Agilent technologies) following the 
manufacturer’s instructions. The following primers were used to generate the indicated 
point mutations (Table 3-M). 
 
Table 3-M 
Mutation Primer Sequence (5’ – 3’) 
sense CACGGTGGTACCGATGGTAAAGATCACTCCAGGTCTGG 
K104F 
antisense CCCAGACCTGGAGTGATCRRRACCATCGGTACCACCGTG 
sense CAGGGCTAGAAGTGCGGGGGCGTTCAAGGAGTCTG 
S320A/T322A 
antisense CAGACTCCTTGAACGCCCCCGCATTCTAGCCCTG 
 
After sequencing, Flag-tagged Fra-2 WT, Fra-2 K104F and Fra-2 S320A/T322A were 
subsequently cloned into pLVX for lentiviral expression. Briefly, 5µg of plasmid DNA of 
pGEM7Zf containing Flag-tagged Fra-2 WT, Fra-2 K104F or Fra-2 S320A/T322A inserts 
and 1µg of plasmid DNA of pLVX was digested with the restriction enzymes EcoRI and 
XhoI (New England Biolabs). Digested pLVX vector was treated with shrimp alkaline 
phosphatase to avoid re-ligation. Digested pGEM7Zf plasmid DNA was separated on a 1% 
agarose gel and insert DNA was purified using QIAquick Gel Extraction Kit (Qiagen). 
Ligation was performed o/n at RT using T4 DNA ligase (Fermentas). Competent bacteria 
(Invitrogen) were transformed by heat shock transformation and plated on Luria Broth (LB) 
plates containing ampicillin and were incubated o/n at 37°C. Eight clones were collected 
from each transformation and grown in 2ml LB media containing ampicillin o/n. Plasmid 
DNA was isolated using QIAprep Spin Miniprep kit (Qiagen). Presence and correct 
orientation of the insert was confirmed by restriction digest with XhoI and XbaI (New 
England Biolabs) and subsequent sequencing. 
4. CELL CULTURE 
4.1. Mouse keratinocyte cell lines 
For long term culture, mouse keratinocyte (mKC) cell lines were isolated from back skin of 
newborn mice as previously described (Nowak and Fuchs, 2009). Briefly, the epidermis 
was separated from the dermis by incubation in 0.75% trypsin (Gibco) at 37°C for 1h. 
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Single epidermal cells were isolated by incubation in media containing 250µg/ml DNaseI 
(Sigma) in a 37°C water bath with frequent shaking. The cell suspension was filtered 
through a 70µm cell strainer. mKCs were cultured on feeders in DMEM (Sigma) media 
containing 0.05mM calcium (Ca2+), L-Glutamine (Gibco), Penicillin, Streptomycin 
(Pen/Strep; Gibco), 15% chelated fetal bovine serum (FBS; Lonza; supplemented with 
insulin, cholera toxin, hydrocortisone, transferrin and  triiodo-L-thyronine) until they 
became feeder-independent. All experiments were performed with feeder-independent 
mKCs up to passage 20. To induce differentiation in culture, Ca2+ was raised from 0.05mM 
to 1.5mM for the indicated time periods. Ezh2 methyltransferase activity was inhibited 
using GSK126 (GlaxoSmithKline) and EPZ6438 (Epizyme) inhibitors at 5µM for 6-48h. 
ERK1/2 kinase activity was inhibited using FR180204 (Tocris Bioscience) at 5µM for up to 
48h.  
4.2. Primary mouse keratinocyte culture 
Isolation and short term culture of primary mKCs from tail skin of adult wildtype, Fra-2f/f 
mice, Fra-2Ep-tetOFF mice and littermate controls was performed as described (Blanpain et 
al., 2004). Briefly, single epidermal cells were isolated as stated above. mKCs were plated 
on coated dishes (Cascade Biologics) in DMEM (Sigma) media containing 8% chelated 
FBS (Lonza), 0.05mM Ca2+ and Pen/Strep. Media was changed to serum-free keratinocyte 
medium (K-SFM Gibco) supplemented with EGF, bovine pituitary extract and Pen/Strep 
12h after plating. Fra-2Ep-tetOFF keratinocytes were cultured in the absence of doxycycline. 
Calcium concentration was raised to 1,5mM for differentiation experiments. 
Fra-2f/f cells were infected with adenoviruses expressing Cre (AdCre), green fluorescent 
protein (AdGFP) or an empty adenovirus (Ad0) purchased from the University of Iowa. 300 
particles per cell were used on day 1 and 4 after plating. Cells were collected for mRNA 
and protein analyses 7 days after plating. 
4.3. Lentiviral production 
Lentiviruses were produced in 293T cells (cultured in DMEM + 10% FBS and Pen/Strep) 
by HEPES-buffered saline–CaCl2 phosphate-mediated transient co-transfection of pLVX 
plasmids and pLP1, pLP2, pLP/VSVG packaging plasmids. Primary WT cells were 
infected with lentiviruses on day 1 and 2 after plating. Primary Fra-2f/f cells were infected 
with AdGFP/AdCre viruses on day 1 and day 4 and with lentiviruses on day 2 and day 3 
after plating. Cells were collected for mRNA and protein analyses 5 days after the last 
lentiviral infection. 
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4.4. Feeder cells 
3T3 fibroblasts were used as feeders for mKCs and were maintained in 10% FBS DMEM 
3:1 F12 (Gibco) with sodium bicarbonate, L-glutamine and Pen/Strep. These cells were 
passaged up to 20 times. Feeders were treated with 10µg/ml mitomycin C for 2h at 37°C 
and washed extensively before mKCs were plated on top. 
 
5. PROTEIN ANALYSES 
5.1. Protein Isolation 
Protein isolation from epidermal tissue or from cultured cells for western blot and IP was 
performed in RIPA buffer (50mM Tris HCl pH7.5, 150mM NaCl, 5mM EDTA, 5mM EGTA, 
1% NP-40) containing protease and phosphatase inhibitors (Roche). Cell lysis buffer 
(#9803 Cell Signaling) was used to isolate protein from epidermal samples for ELISA. 
Protein lysates were quantified using Pierce BCA protein Assay Reagent (Thermos 
Scientific).  
5.2. Cytokine analyses 
BD CBA Flex kits (Beckton-Dickinson) were used to measure IL-6, IL-17, IL-1α, TNFα and 
G-CSF levels in serum following manufacturers instructions. Serum was diluted 1:4. 
A single ELISA kit (R&D Biosciences) was used to measure TSLP levels in epidermal 
lysates and serum following manufacturers instructions. Serum was diluted 1:4. 
5.3. p65/NF-κB transcription factor activity assay 
p65 activity was measured in nuclear extracts isolated from epidermis or primary 
keratinocytes using a DNA-binding ELISA kit (TransAM, Active Motif). Briefly, nuclei were 
isolated by cell lysis in hypotonic buffer (20mM Hepes, pH 7.5, 5mM NaF, 10µM Na2MoO4, 
0.1mM EDTA, 0.5% NP-40) and nuclear lysis in complete lysis buffer (provided in the kit). 
10µg of nuclear extracts were bound to immobilized oligonucleotides containing the NF-κB 
consensus site for 1h at RT. After washing, the primary p65 HRP-conjugated antibody was 
incubated with the bound proteins for 1h at room temperature. After adding the developing 
solution (provided in the kit), absorbance was read on a spectrophotometer at 450nm.  
5.4. Western blots 
Western blot (WB) analysis was performed according to standard procedures. Equal 
amounts of protein (20-50µg) were separated by SDS-PAGE and transferred to 
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nitrocellulose membranes (Whatman). The following primary Abs were used: Fra-2 (1:100, 
CNIO Monoclonal Antibody Unit), Ezh2 (1:1000, #AC22 Cell Signaling), p-Fra-1 (Ser265) 
(1:1000, #3880, Cell Signaling), pan-methyl lysine (1:200, ab174719, Abcam), p-Ser 
(1:500, P5747, Sigma), p-ERK1/2 (Thr202/Tyr204) (1:1000, #4370), ERK1/2 (1:1000, 
#4695, Cell Signaling), ΔNp63 (1:500, sc-8609, Santa Cruz), Suz12 (ab12073, Abcam), 
Flg (1:1000, Covance), Lor (1:1000, Covance), Vinculin (1:1000, V9131, Sigma). Blots 
were incubated with the appropriate horseradish peroxidase-couples secondary Abs (GE 
Healthcare) and developed using the Amersham ECL Plus Western Blotting Detection 
Reagent (GE Healthcare) and Amersham ECL Hyperfilms (GE Healthcare). 
5.5. Immunoprecipitation  
2-5µg of Fra-2 (CNIO Monoclonal Antibody Unit), Ezh2 (5246, Cell Signaling), and pan-
methyl lysine (ab174719, Abcam) antibodies were incubated with 20µl of Dynabead 
protein G magnetic beads (Invitrogen) for 3h-over night. 1mg of precleared cell extract per 
immunoprecipitation (IP) was used as input material and incubated with antibody-
conjugated beads over night at 4ºC under rotation. A magnetic rack was used to separate 
beads from protein extracts/buffer.  
5.5.1. Immuno-complex elution for WB 
IPs were extensively washed with RIPA buffer and captured proteins were eluted from the 
antibody-coupled beads using Laemmli buffer (125mM Tris-HCl pH 6.8, 20% Glycerol, 4% 
SDS, 0.005% Bromophenol blue, 10% β-Mercaptoethanol) for Fra-2, methyl lysine and p-
Fra-1 western blot analysis or XT sample buffer (Biorad) without β-Mercaptoethanol for 
Ezh2 western blot analysis.  
5.5.2. Immuno-complex elution and digestion for Mass Spectrometry  
IPs were extensively washed with RIPA buffer and captured proteins were eluted from the 
antibody-coupled beads by incubation at 45°C with 200µL of 8M Urea in 100mM Tris-HCl 
pH 8.0.  Protein samples were processed using filter aided sample preparation (FASP) 
method (Wisniewski et al., 2009b), digested at 25°C overnight using endoproteinase Lys-C 
(Wako Pure Chemical Industries, Osaka, Japan) at 1:50 enzyme to protein ratio followed 
by digestion with trypsin (Promega, Madison, WI) at 1:100 enzyme to protein ratio for 6h at 
37°C. Peptides were subjected to tip-based strong anion exchange fractionation (SAX) 
using the described protocol (Wisniewski et al., 2009a). In addition, a second 
immunoprecipitation experiment was carried out in which the protein eluate was separated 
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by SDS-PAGE. For in-gel digestion, bands were excised and proteins were reduced with 
15mM TCEP in 50mM ammonium bicarbonate for 45 minutes at 60°C and alkylated with 
50mM 2-chloroacetamide in 50mM ammonium bicarbonate for 30 minutes at 25°C in the 
dark. Proteins were subsequently digested at 37°C overnight with trypsin at 1:200 enzyme 
to protein ratio. 
5.6. Mass Spectrometry Analysis 
For mass spectrometry (MS) experiments, up to 20mg of precleared protein lysate was 
used per IP. 
5.6.1. LC-MS/MS analysis 
Desalted peptides were separated by reversed-phase chromatography using a nanoLC 
Ultra system (Eksigent), directly coupled with a LTQ-Orbitrap Velos instrument (Thermo 
Fisher Scientific) via nanoelectrospray source (ProxeonBiosystem). Peptides were loaded 
onto the column (Dr. Maisch GmbH, Reprosil-Pur C18-AQ 3 µm, 200x0.075 mm), with a 
previous trapping column step (0.10 x 20 mm, Reprosil-Pur C18-AQ, 3 µm, 120Å), during 
10 min with a flow rate of 2.5µL/min of loading buffer (0.1% FA). Elution from the column 
was made with a 120 min linear gradient or a 45 minutes linear gradient (in-solution and 
in-gel respectively) (buffer A: 4% ACN, 0.1%FA; buffer B: 100% ACN, 0.1%FA) at 
300nL/min. The peptides were directly electrosprayed into the mass spectrometer using a 
PicoTip emitter (360/20 OD/ID µm tip ID 10 µm, New Objective) a 1.4 kV spray voltage 
with a heated capillary temperature of 325°C and S-Lens of 60%. Mass spectra were 
acquired in a data-dependent manner, with an automatic switch between MS and MS/MS 
scans using a top 15 or a top 5 method (in-solution and in-gel respectively) with a 
threshold signal of 800 counts. MS spectra were acquired with a resolution of 60000 
(FWHM) at 400 m/z in the Orbitrap, scanning a mass range between 350 and 1500m/z. 
Peptide fragmentation was performed using collision induced dissociation (CID) and 
fragment ions were detected in the linear ion trap. The normalized collision energy was set 
to 35%, the Q value to 0.25 and the activation time to 10 ms. The maximum ion injection 
times for the survey scan and the MS/MS scans were 500 ms and 100 ms respectively 
and the ion target values were set to 1E6 and 5000, respectively for each scan mode. 
5.6.2. Mass Spectrometry data analysis 
Raw files were analyzed by Proteome Discoverer (version 1.4.1.14) against a mouse 
database (Swiss-Prot canonical, 17002 sequences, Jan22_2014 release, including 
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common contaminant proteins). Oxidation of methionines, monomethylation, dimethylation 
and trimethylation of lysines were set as variable modifications, whereas 
carbamidomethylation of cysteines was considered as fixed modification in the SequestHT 
search engine. Minimal peptide length was set to 6 amino acids, a maximum of two 
missed-cleavages were allowed. Peptides were filtered at 1% FDR by using Percolator.  
 
6. CHROMATIN IMMUNOPRECIPITATION 
Chromatin immunoprecipitation (ChIP) was performed using cultured mouse keratinocytes 
fixed in 1% formaldehyde. Nuclear lysates were obtained by lysis of cell membranes in a 
hypotonic buffer (50mM, HEPES-KOH pH 7.5, 140mM NaCl, 1mM EDTA, 10% Glycerol, 
0.5% NP-40, 0.25% Triton-X-100) and clearance of detergents (10mM Tris-HCL pH 8.0, 
200mM NaCl, 1mM EDTA, 0.5mM EGTA). Nuclei were resuspended in ChIP sonication 
buffer (100mM NaCl, 10mM TrisHCl pH 8, 1mM EDTA, 0.5mM EGTA, 0.1%Na-
Deoxycholate, 0,5% N-lauroylsarcosine). Sonication was performed using a Covaris 
ultrasound device. Whole nuclear extract was quantified with BCA protein assay and 0.5-
1mg of protein was used for preclearing with 10µl of protein G dynabeads. 
Immunoprecipitation was performed with 2-5µg of antibodies coupled to protein G 
dynabeads against Fra-2 (CNIO Monoclonal Antibody Unit), Ezh2 (#5246, Cell Signaling), 
Suz12 (ab12073, Abcam), H3K27me3 (ab6002, Abcam) and H3K4me3 (ab8580, Abcam) 
over night at 4ºC. Rat or rabbit IgGs were used as a negative control (Millipore). After 
washing once with low salt (1% Triton X-100, 0.1% SDS, 2mM EDTA pH 8.0, 150mM 
NaCl, 20mM Tris-HCl pH 8.0), once with high salt buffer (1% Triton X-100, 0.1% SDS, 
2mM EDTA pH 8.0, 500mM NaCl, 20mM Tris-HCl pH 8.0), once with LiCl buffer (1% NP-
40, 1% Na-Deoxycholate, 1mM EDTA, 250mM LiCl, 20mM Tris-HCl pH8.0), and once with 
TE Buffer (10mM Tris, 8.0, 1mM EDTA), Protein/DNA complexes were eluted from beads 
and DNA was decrosslinked at 65ºC in elution buffer (1%SDS, 10mM EDTA, 50mM Tris-
HCl pH 8) overnight. Eluate was treated with RNase A (Sigma) for 2h at 37ºC and with 
Proteinase K (VWR) for 2h at 55ºC. DNA was recovered with Phenol/Chlorophorm 
extraction and amplified using GoTag PCR master mix (Promega) and primers specific for 
AP-1 binding sites of EDC promoters using an Ep-Realplex light cycler (Eppendorf). 
Primer sequences can be found in Table 4-M. The position of the AP-1 consensus site 
upstream the transcription start site is indicated in parentheses.  
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Table 4-M 
Allele Name Primer Sequence (5’ – 3’) 
sense CCCACTTGCTGAAAAGGTCAA Flg 
(-1400bp) antisense CAGGTTTGGCAGGTGCTGTA 
sense GACCTGAACTGCAAATGGACAC S100A11 
(-200bp) antisense CGGTGCTCTAGACTCAGCTC 
sense TCTTAGAAGCTAGGAAGTTTTCCA Lce1k 
(-1000bp) antisense ACAATGAGAGAAATGCTGCCC 
sense TTTCTGCCCCCTTCTGCAC S100A7 
(-3000bp) antisense CCAAACAGGTGGTTCTCATAGG 
sense ATGACCAACCTGCTCACTGT Lor 
(-1400bp) antisense GAGGGAAGGAGGTGATGCTG 
sense TGGTGGTGATGAATCAGGTCAT 
Tchhl1 
antisense ATGTGGGGCAATGTGGGG 
sense GTGTCAACAGCTGGGCCTTTCTTT TSLP 
(-1200bp) antisense GTGGGTTGGGTTAAGATTTGCGCT 
sense TGTCTGGAATGTGGTGGTTTGA Intergenic 
mChr3 antisense GCCCACTGCTATAATTAGGAAGGA 
 
7. FACS 
Basal and differentiated mKCs were isolated from the back skins of newborn mice as 
described above. Back skins from 6 mice were pooled. Cell suspensions were stained for 
30 min at 4°C using a phycoerythrin-conjugated rat anti-CD49f (integrin α6 chain) antibody 
(#555736, BD) as previously described (Nowak and Fuchs, 2009). Cells were sorted on a 
FACSAria Ilu using CellQuest Pro software (BD). 
8. RT-qPCR 
RNA was isolated from epidermal tissue and cultured cells using Trizol reagent 
(Invitrogen). cDNA synthesis was performed using 2µg of total RNA using "Ready-to-go 
You-Prime IT First-Strand-Beads" (Amersham Pharmacia Biotech) and random primers 
(Invitrogen). RNA was isolated from FACS purified cells using RNeasy Mini kit (Qiagen). 
cDNA synthesis was performed using 100ng of total RNA using SuperScript VILO cDNA 
Synthesis Kit. PCR products were quantified using GoTag PCR master mix (Promega), 
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Ep-Realplex thermal cycler (Eppendorf) and ΔΔCT method. Primer sequences can be 
found in Table 5-M. 
Table 5-M 
Allele Name Primer Sequence (5’ – 3’) 
sense GGAGGCATGGTGGAACTGA 
Flg 
antisense TGTTTATCTTTTCCCTCACTTCTACATC 
sense ACAGCGGGAAGGATGGAAAC 
S100A11 
antisense TGGAAATCTAGCTGCCCGTC 
sense GGACTGCTGCTGACCTGAGT 
Lce1k 
antisense ACAGAAGGGGTAGCAACATGG 
sense TGAAGGGTCCATCAGTCA 
S100A7 
antisense CTAGTAGAGGCTGTGCT 
sense TCACTCATCTTCCCTGGTGCTT 
Lor 
antisense GTCTTTCCACAACCCACAGGA 
sense ATTCCGCTTGCTCTCACTCCT 
Tchhl1 
antisense GGTTCAACTTTCTCTCCACAGC 
sense GAGGACTGTGAGAGCAAGCCAG 
TSLP 
antisense GGCAGTGGTCATTGAGGGCTT 
sense CGCTCACATCCCTACAGTCC 
Fra-2 
antisense CCTGCAGCTTCTCTGTCAGC 
sense CTCCCGGCACTTCAAACCT 
Fra-2 Flag 
antisense TTGTCGTCGTCGTCCTTGTA 
sense ATCCCGGGAACTTTGACACC 
Fra-2ΔGFP 
antisense GTGAACCGCATCGAGCTGAAGGG 
sense CTCTACGTAGTTACCACAACAAT 
Keratin 1 
antisense CAATCCTCTACGTAGACGTA 
sense AGAAGGCCTTGAGCAACCTC 
S100A8 
antisense TGGCTGTCTTTGTGAGATGC 
sense CAGAAGGCAGCTTTACGATG 
Lcn2 
antisense TCTGATCCAGTAGCGACAGC 
sense GTGTTCCTACCCCCAATGTG 
GAPDH 
antisense GGAGACAACCTGGTCCTCAG 
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sense GTCCAGGTCCTCCATGATGT 
S100A9 
antisense TCAGACAAATGGTGGAAGCA 
sense AACCAGGGTGTGTCCATGTC 
p65 
antisense CCGGAGAGACCATTGGGAAG 
 
9. STATISTICAL ANALYSIS  
Unless stated differently, all experiments were performed 3 times. Results are presented 
as mean ± standard deviation (SD) of triplicates. p-values were calculated using two-tailed 
student’s t-test. * indicates p<0.05, considered significant. 
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1. Fra-2 regulates epidermal differentiation 
1.1. Fra-2 protein levels are increased during keratinocyte differentiation  
To define the role of Fra-2 in epithelial homeostasis, Fra-2 expression was evaluated in 
cultured mouse keratinocytes (mKCs) in basal conditions and upon calcium (Ca2+)-induced 
differentiation. Fra-2 mRNA levels did not change during mKC differentiation (Figure 1A). 
However, increased Fra-2 protein was detected upon Ca2+ treatment (Figure 1B). Gene 
expression analyses of FACS-purified epidermal keratinocytes obtained from newborn 
pups further confirmed no difference of Fra-2 mRNA between basal mKCs (α6 integrin 
high) and differentiated mKCs (α6 integrin low) (Figure 1C). In mouse skin tissue sections, 
immunofluorescence (IF) staining revealed that Fra-2 protein was expressed in all 
epidermal layers. However, a gradient was observed, with highest expression in terminally 
differentiated keratinocytes (Figure 1D, arrows).  
 
 
 
 
Figure 1. Fra-2 induces terminal epidermal differentiation. (A) Fra-2 mRNA expression during 
calcium (Ca2+)-induced in vitro mouse keratinocyte (mKC) differentiation; Keratin 1 (K1) and 
Filaggrin (Flg) expression indicate induction of early and terminal epidermal differentiation markers, 
respectively; n=3; (B) Fra-2 protein expression during Ca2+-induced in vitro mKC differentiation; 
loss of ΔNp63 indicates induction of differentiation; n=4. (C) Fra-2 mRNA expression of basal (α6 
integrin high) and differentiated (α6 integrin low) mKCs isolated from newborn pups; K1 and Flg 
indicate induction of early and terminal epidermal differentiation markers; n=3; (D) Fra-2 
immunofluorescence (IF) of wild-type skin at embryonic day 17.5 (E17.5); n=6; 40x magnification. 
* p<0.05; bars represent mean ± standard deviation (SD). 
 
1.2. Fra-2 induces EDC gene expression and binds EDC gene promoters 
Based on the increased Fra-2 protein expression during mKC differentiation, a regulatory 
function of Fra-2 on terminal epidermal differentiation genes was next investigated. For 
this purpose, primary wild-type (WT) mKCs were infected with lentiviruses expressing full 
length, Flag-tagged, Fra-2 (Fra-2 WT) or empty vector (pLVX) and the expression of EDC 
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genes was evaluated. Efficient Fra-2 over-expression was verified by qRT-PCR. Notably, 
lentiviral expression of Fra-2 WT induced EDC gene expression in primary mKCs (Figure 
2A). To test whether Fra-2 directly regulates and binds EDC gene promoters, chromatin 
immunoprecipitation (ChIP) experiments in basal mKCs and during differentiation were 
performed. Rat IgGs were used as negative control for Fra-2 ChIP experiments. mRNA 
from the same samples was collected to confirm epidermal differentiation and to correlate 
binding with gene expression as shown in Figure 2B. Fra-2 associated with EDC 
promoters in regions with conserved AP-1 consensus sites. Surprisingly, Fra-2 was bound 
at EDC gene promoters under differentiation conditions, but also in basal conditions, when 
EDC genes are not expressed (Figure 2C). Collectively these findings indicate that Fra-2 
induces EDC gene expression by direct promoter binding and suggest that even though 
expressed and bound at target gene promoters, Fra-2 is likely inactive in basal cells.  
 
 
 
Figure 2. Fra-2 induces EDC gene expression and binds EDC gene promoters. (A) Differential 
Fra-2 and EDC gene expression of primary mKCs expressing Fra-2 WT compared to empty vector 
infected cells; n=3. (B) EDC mRNA expression analyses during wild-type mKC differentiation (0-
72h Ca2+); n=5; (C) Chromatin-immunoprecipitation (ChIP) analyses of Fra-2 at EDC promoters 
during wildtype mKC differentiation (0-72h Ca2+); n=5; * p<0.05; bars represent mean ±SD.	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1.3. Fra-2 and Ezh2 co-regulate epidermal differentiation genes 
Fra-2 ChIP data suggested that transcriptional repressors might co-regulate EDC genes 
together with AP-1 transcription factors in basal cells. Since PRC2 represses EDC genes 
(Ezhkova et al., 2009; Mejetta et al., 2011), ChIP studies were performed using antibodies 
against the PRC2 subunits Ezh2, Suz12 and the repressive histone mark H3K27me3 
(Figure 3).  
 
 
 
Figure 3. Ezh2/PRC2 co-regulate epidermal differentiation genes. (A-D) ChIP analyses of 
negative control IgGs (A) Ezh2 (B), Suz12 (C) and H3K27me3 (D) n=3; (E) Ezh2 and Suz12 
protein expression during in vitro mKC differentiation; n=4; (F) ChIP analyses of H3K4me3 during 
mKC differentiation (0-72h Ca2+); n=3; * p<0.05, bars represent mean ±SD. 
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Rabbit IgGs were used as negative control for all ChIP experiments (Figure 3A). The 
transcription start sites (TSS) of Fra-2-bound EDC genes were found enriched for Ezh2 
and Suz12 and positive for H3K27me3 in basal cells. Importantly, the associations of 
PRC2 subunits as well as H3K27me3 levels were reduced upon Ca2+-induced 
differentiation (Figure 3B-D). These findings are consistent with the drastic reduction of 
Ezh2 and Suz12 protein levels during mKC differentiation (Figure 3E). In addition to the 
reduction of the repressive H3K27me3 modification, H3K4me3, a histone modification 
associated with transcriptional activation, was increased upon mKC differentiation (Figure 
3F). These results show that Fra-2/AP-1 and Ezh2/PRC2 co-occupy EDC promoters in 
basal keratinocytes and that the removal of PRC2 subunits correlates with transcriptional 
activity. 	  
1.4. Fra-2 and Ezh2 physically interact and Fra-2 is methylated on lysine(s) 
Besides modifying histones, Ezh2 methylates non-histone substrates, such as some 
transcription factors, thereby regulating their transcriptional activity (He et al., 2012; Kim et 
al., 2013; Lee et al., 2012; Xu et al., 2012). Therefore, we investigated a potential histone 
methylation-independent role of Ezh2 on Fra-2 during epidermal differentiation employing 
co-immunoprecipitations (coIP). Ezh2 co-precipitated with Fra-2 and Fra-2 co-precipitated 
with Ezh2 in protein lysates isolated from basal keratinocytes (Figure 4A,B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Fra-2 and Ezh2 physically interact. (A,B) Co-immunoprecipitation (coIP) of Ezh2 (A) 
and coIP of Fra-2 (B) and Western blot (WB) analysis of Ezh2, Fra-2 and methylated lysine (methyl 
K) in basal mKCs; n=5. (C) CoIP of Fra-2 and WB analysis of Ezh2, Fra-2 and methyl K during 
mKC differentiation (0-48h Ca2+); n=5; TCL=total cell lysate. 
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Since Ezh2 methylates specific lysine residues of histone proteins and Ezh2 interacts with 
Fra-2, the methylation status of Fra-2 was investigated. Using immunoprecipitated Fra-2 
and an antibody against pan-methyl lysine (methyl K), methylated Fra-2 was detected in 
basal mKCs (Figure 4B). CoIP experiments revealed that the Fra-2-Ezh2 interaction was 
reduced upon mKC differentiation, consistent with the reduction of Ezh2 protein levels 
(Figure 4C). In agreement with PRC2 reduction upon differentiation, Fra-2 methylation 
was absent in differentiated mKCs (Figure 4C). These data demonstrate that Fra-2 and 
Ezh2 interact and that Fra-2 is methylated on lysine residues in basal cells, correlating 
with transcriptional inactivity at the EDC locus. 
1.5. Ezh2 inhibition reduces Fra-2 methylation and promotes differentiation 
To assess a role of Ezh2 in Fra-2 methylation, Ezh2 was pharmacologically targeted using 
two small molecules, GSK126 and EPZ6438, inhibitors of the methyltransferase domain of 
Ezh2. The methylation status of Fra-2 protein in basal keratinocytes was assessed by IP 
for methylated lysine and WB for Fra-2. In both cases, Fra-2 methylation was decreased 
upon Ezh2 inhibition (Figure 5A). 
Pharmacological inhibition of Ezh2 was not sufficient to induce terminal mKC 
differentiation. However, GSK126 inhibitor-treated cells differentiated prematurely upon 
Ca2+ treatment (Figure 5B). These findings indicate that upon inhibition of Ezh2-mediated 
methylation, an additional stimulus is required to induce mKC differentiation.  
 
 
Figure 5. Reduced Fra-2 methylation and increased expression of EDC genes upon 
inhibition of Ezh2. (A) IP of methyl K and WB of Fra-2 upon Ezh2 inhibition with GSK126 and 
EPZ6438 in basal mKCs; n=3. (B) mRNA expression analyses of EDC genes upon Ezh2 inhibition 
(GSK126) for 24h with or without Ca2+; n=3; * p<0.05, bars represent mean ±SD. 
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1.6. Fra-2 is methylated on lysine 104 in basal mKCs 
To investigate the molecular nature of Fra-2 lysine methylation, endogenous Fra-2 was 
immunoprecipitated from basal mKC protein extracts followed by mass spectrometry (MS) 
analyses. In two independent experimental approaches (see Materials and Methods), MS 
analyses identified mono- and dimethylation of lysine 104 (K104) (Figure 6A-D). 
 
 
Figure 6. Fra-2 is methylated on lysine 104 (K104) in basal mKCs. (A) Sequence coverage of 
Fra-2 identified by MS analysis, in which red residues represent the identified peptides. (B-D) MS 
spectra of 89-104 Fra-2 peptide (framed in A) found unmodified (B), mono-methylated on K104 (C) 
and di-methylated on K104 (D). Mass error, identification score and posterior error probability (PEP) 
are shown for the 3 different Fra-2 89-104 peptides.  
 
1.7. Mimicking Fra-2 lysine methylation decreases Fra-2 transcriptional activity 
and EDC gene expression in primary mKCs in vitro 
Site-directed mutagenesis was next performed to substitute K104 with phenylalanine 
(K104F), mimicking lysine methylation (Huq et al., 2007). Primary WT mKCs were infected 
with lentiviruses expressing Fra-2 WT, Fra-2 K104F or empty vector (pLVX). Efficient Fra-
2 expression was verified by WB and qRT-PCR with primers specific for total and 
ectopically expressed Fra-2 (Figure 7A-C). Lentivirus-mediated expression of Fra-2 WT 
induced EDC gene expression in primary WT mKCs. However, Fra-2 K104F was inactive 
in the same setting as shown in Figure 7C. These results suggest that lysine methylation 
renders Fra-2 transcriptionally inactive. 
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Figure 7. Mimicking Fra-2 K104 methylation reduces the transcriptional activity of Fra-2. 
(A,B) Fra-2 protein (A) and Fra-2 Flag gene (B) expression of primary mKCs infected with 
lentiviruses expressing wild-type Fra-2 (Fra-2 WT) or mutant Fra-2 mimicking lysine methylation 
(Fra-2 K104F) compared to empty vector infected cells (pLVX); n=3. (C) Differential Fra-2 and EDC 
gene expression of primary mKCs expressing Fra-2 WT or Fra-2 K104F compared to empty vector 
infected cells; n=3; * p<0.05, bars represent mean ±SD. 
 
1.8. Fra-2 is phosphorylated and stabilized by ERK1/2 upon mKC differentiation 
Since Fra-2 mRNA remained unaltered during mKC differentiation, although an increase of 
total Fra-2 protein was detected, we hypothesized that Fra-2 was stabilized at the protein 
level by posttranslational modifications. ERK1/2 kinases were shown to stabilize Fra-2 
protein by C-terminal serine 320 (S320) and threonine 322 (T322) phosphorylation (Alli et 
al., 2013). We therefore investigated ERK1/2 activity during mKC differentiation. ERK1/2 
phosphorylation was detected in suprabasal keratinocytes of developing embryos at 
embryonic day 17.5 (E17.5) (Figure 8A) and upon Ca2+-induced differentiation in vitro 
(Figure 8B). To investigate the C-terminal Fra-2 serine phosphorylation, a phospho-Fra-1 
antibody reacting with a conserved phospho peptide on Fra-1 and Fra-2 (Ser267 and 
Ser320, respectively) was used on immunoprecipitated Fra-2 at different time points of 
mKC differentiation. C-terminal Fra-2 phosphorylation was increased upon Ca2+-induced 
differentiation correlating with increased ERK1/2 phosphorylation (Figure 8B,C). 
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Figure 8. Fra-2 is phosphorylated and stabilized by ERK1/2 upon mKC differentiation (A) p-
ERK1/2 IHC in skin of wildtype embryos at E17.5; arrows point towards suprabasal expression, 
dashed white line indicates basement membrane; n=3. (B) ERK1/2 activation shown by p-ERK1/2 
WB during in vitro mKC differentiation (0-72h Ca2+); n=3. (C) IP of Fra-2 during mKC differentiation 
(0-48h Ca2+) and WB analyses of Fra-2 and p-Fra-1/2; n=3. (D) WB analysis of Fra-2 upon Ca2+ 
treatment (48h) and ERK1/2 inhibition with FR180204; n=3. (E) IP of Fra-2 upon Ca2+ treatment 
(48h) and ERK1/2 inhibition with FR180204 and WB of Fra-2 and p-Fra-1/2; n=3. (F) mRNA 
expression analyses of EDC genes upon Ca2+ treatment (48h) and ERK1/2 inhibition with 
FR180204; n=3, * p<0.05, bars represent mean ±SD. 
 
A small molecule inhibitor of ERK1/2 (FR180204) was next used. ERK1/2 inhibitor 
treatment of mKCs led to reduced Fra-2 protein levels, reduced Fra-2 phosphorylation as 
well as reduced EDC gene expression upon Ca2+ treatment (Figure 8D-F). Altogether, 
these data suggest that Fra-2 is stabilized by C-terminal phosphorylation during mKC 
differentiation and that ERK1/2 activation correlates with Fra-2 phosphorylation. 
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1.9. C-terminal phosphorylation increases the transcriptional activity of Fra-2 and 
EDC gene expression in primary mKCs in vitro 
We next functionally validated the role of C-terminal Fra-2 phosphorylation on EDC gene 
expression and mutated S320 and T322 to alanine (S320A/T322A), which cannot be 
phosphorylated. Primary mKCs were infected with lentiviruses expressing Fra-2 WT, Fra-2 
S320A/T322A or empty vector. Efficient Fra-2 expression was verified by WB and qRT-
PCR with primers specific for total and ectopically expressed Fra-2 (Figure 9A-C). While 
lentivirus-mediated expression of Fra-2 WT induced EDC gene expression, expression of 
Fra-2 S320A/T322A did not (Figure 9C). These findings indicate that the ability of Fra-2 to 
induce EDC gene expression is reduced upon mutation of C-terminal phospho-acceptor 
sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Mutation of Fra-2 C-terminal phospho-acceptor sites reduces the transcriptional 
activity of Fra-2. (A,B) Fra-2 protein (A) and Fra-2 Flag gene (B) expression of primary mKCs 
infected with lentiviruses expressing Fra-2 WT or mutant Fra-2 deficient for C-terminal phospho-
acceptor sites (Fra-2 S320A/T322A) compared to empty vector infected cells; n=3. (C) Differential 
Fra-2 and EDC gene expression of primary mKCs expressing Fra-2 WT or Fra-2 S320A/T322A 
compared to empty vector infected cells; n=3; * p<0.05, bars represent mean ±SD. 
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In conclusion, these results show an inverse kinetic of lysine methylation - loss of 
interaction with Ezh2 - and ERK1/2-mediated serine phosphorylation of Fra-2. At EDC 
promoters, methylated but not phosphorylated Fra-2 correlates with EDC gene 
inactivation, while loss of Fra-2 methylation, ERK1/2 activation and Fra-2 phosphorylation 
correlates with active Fra-2-dependent gene expression (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Schematic model of EDC gene regulation by Fra-2, Ezh2 and ERK1/2: in basal cells, 
methylated Fra-2 (Fra-2 Me) bound at TPA-responsive elements (TREs) of EDC gene promoters 
and interacting with Ezh2 prevents EDC gene expression; upon mKC differentiation, Fra-2 
becomes phosphorylated (Fra-2 P) by ERK1/2 and loses its methylation, Ezh2 protein levels and 
histone 3 lysine 27 (H3K27) methylation at transcription start sites (TSS) of EDC promoters are 
reduced, which together induce EDC gene expression.  
 
1.10. Fra-2 induces terminal epidermal differentiation in vivo 
Given our biochemistry data from in vitro experiments, we decided to investigate the 
function of Fra-2 in regulating epidermal differentiation in vivo. For this purpose, 
genetically engineered mouse models (GEMMs) with epithelial-specific ectopic 
expression, as well as specific deletion of Fra-2 were generated. The expression of genes 
located within the EDC such as Flg, Lor, Tchhl1 and Lce1k was analyzed in these model 
systems. 
Upon ectopic expression of Fra-2 in K5-expressing epithelia (Fra-2Ep-tetOFF), a significant 
increase of EDC gene transcripts was detected in epidermal samples of embryos at E17.5 
(Figure 11A). This finding recapitulated our results from in vitro experiments with 
lentivirus-mediated over-expression of Fra-2.     
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Figure 11. Fra-2 induces terminal epidermal differentiation. (A) Differential EDC gene and Fra-
2 expression in epidermal samples of mutants ectopically expressing Fra-2 (Fra-2Ep-tetOFF) 
compared to control littermates at E17.5; n=6/genotype. (B) Basal cell marker expression (K5, 
green) and late differentiation marker expression (Lor, red, upper panel; Flg, red, lower panel) in Co 
and Fra-2Ep-tetOFF skin at E17.5; n=6/genotype; 40x magnification; white bars indicate thickness of 
differentiated epidermal layers. (C,D) Quantification of Figure 11B; mean Lor (C) and Flg (D) 
fluorescence intensity/40x field; n=10 fields/genotype. (E) Differential EDC gene and Fra-2 
expression in primary Fra-2Ep-tetOFF mKCs compared to control mKCs under basal conditions and 
upon Ca2+ treatment for 24h in vitro; n=3; * p<0.05; bars represent mean ±SD. 
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The increase of EDC gene expression was accompanied by an increase of terminally 
differentiated epidermal layers in Fra-2Ep-tetOFF mutants (Figure 11B, quantified in Figure 
11C,D).  
The consequences of increased Fra-2 expression on mKC homeostasis under stress 
conditions were next investigated. Primary mKCs isolated from Fra-2Ep-tetOFF mutants 
underwent precocious differentiation in culture characterized by increased expression of 
terminal differentiation genes at basal conditions, which was more pronounced upon Ca2+ 
treatment (Figure 11E), again confirming our previous in vitro results. 
Collectively, these findings suggest that Fra-2 induces terminal mKC differentiation in vivo 
and in primary mKCs in vitro, while the proliferation of basal mKCs in vivo, assessed by 
Ki67 staining, remained unaffected (Figure 12A,B). 
 
Figure 12. Ectopic Fra-2 expression does not affect mKC proliferation. (A) Basal cell marker 
expression (K5, green) and proliferation marker expression (Ki67, red) in Co and Fra-2Ep-tetOFF 
embryos at E17.5; n=5/genotype; 20x magnification. (B) Quantification of Figure 12A, K5+/Ki67+ 
cells/20x field; n=10 fields/genotype; bars represent mean ±SD. 
 
To validate these findings in a more disease-relevant setting, Fra-2 was ectopically 
expressed in papilloma-prone K5-SOS-F transgenic mice (Fra-2Ep-tetOFF SOS+). 
Interestingly, skin papillomas of poorly differentiated SOS+ mice show high levels of Ezh2 
and express Fra-2 (Figure 13).  
 
Figure 13. SOS+ papillomas express Ezh2 and Fra-2. IF analysis of Fra-2 (green) and Ezh2 
(red) in SOS+ mice at 5 weeks of age; n=5; nuclei are stained with dapi (blue). 
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Figure 14. Fra-2 suppresses skin papilloma growth in SOS+ mice by inducing differentiation. 
(A) Macroscopic appearance of SOS+ and Fra-2Ep-tetOFF SOS+ papillomas at 5 weeks of age; 
n=6/genotype. (B) Analyses of SOS+ and Fra-2Ep-tetOFF SOS+ papillomas. H&E (upper panel), basal 
cell marker expression (K5, green) and late differentiation marker expression (Lor, red, middle 
panel; Flg, red, lower panel) in SOS+ and Fra-2Ep-tetOFF SOS+ papillomas at 5 weeks of age; 20x 
magnification, insert depicts 40x magnification; n=6/genotype. (C,D) Quantification of Figure 14B: 
mean Lor (C) and Flg (D) fluorescence intensity/20x field; n=10 fields/genotype. (E) Differential 
EDC gene and Fra-2 expression in Co, Fra-2Ep-tetOFF, SOS+ and Fra-2Ep-tetOFF SOS+ mice at 5 
weeks of age; n=4/genotype; * p<0.05; bars represent mean ±SD. 
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Importantly, ectopic expression of Fra-2 in this background strongly suppressed skin 
papilloma growth with significantly smaller lesions in Fra-2Ep-tetOFF SOS+ mice (Figure 14A, 
B H&E upper panel). Importantly, increased expression of EDC genes was detected by IF 
(Figure 14B, middle and lower panel, quantified in Figure 14C,D) and mRNA analyses 
(Figure 14E), while no changes in proliferation were observed (Figure 15A,B).  
These results demonstrate that epidermal Fra-2 can induce EDC gene expression under 
stress conditions and functions as a suppressor of papilloma growth due to the induction 
of epidermal differentiation. 
 
Figure 15. Ectopic Fra-2 expression does not affect mKC proliferation in SOS+ mice. (A) 
Proliferation marker expression (Ki67, brown) in SOS+ and Fra-2Ep-tetOFF SOS+ mice at 5 weeks of 
age; n=5/genotype. (B) Quantification of Figure 15A, Ki67+ cells/field; n=5 fields/genotype; bars 
represent mean ±SD. 
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1.11. Fra-2 is necessary for proper epidermal differentiation 
GEMMs with Fra-2 deletion in the differentiated compartment of the epidermis (suprabasal 
deletion with FoxN1-Cre; Fra-2Δsb) and with Fra-2 deletion in the entire epidermis (basal 
deletion with K5-Cre; Fra-2Δep) were generated (Figure 16A).  
 
Figure 16. Fra-2/AP-1 is necessary for proper epidermal differentiation. (A) H&E and Fra-2 IF 
of Co (Fra-2f/f), Fra-2Δsb (Fra-2f/f; FoxN1 Cre+/T) and Fra-2Δep (Fra-2f/f; K5 Cre+/T) embryos at E17.5; 
n=6/genotype; 40x magnification. (B) Toluidine blue dye penetration assay in Co, Fra-2Δsb and Fra-
2Δep embryos at E17.5; n=6/genotype. (C) Proliferation/basal cell marker expression (Ki67, green, 
upper panel; K5, green, lower panel) and late differentiation marker expression (Lor, red, upper 
panel; Flg, red, lower panel) in Co, Fra-2Δsb and Fra-2Δep embryos at E17.5; n=6/genotype; 40x 
magnification. (D) Differential EDC gene expression in Fra-2Δsb and Fra-2Δep embryos compared to 
control littermates at E17.5; n=4/genotype; * p<0.05, bars represent mean ±SD. 
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While macroscopically indistinguishable from control littermates at E17.5, Toluidine blue 
dye penetration assays, performed to assess the functionality of the outside-in-barrier, 
revealed a persistent defect in skin barrier formation in both Fra-2Δsb and Fra-2Δep mutants 
(Figure 16B). Importantly, we measured a significant reduction in the expression of EDC 
genes in these mutants (Figure 16C, D). Thus, the observed skin barrier defect is likely a 
consequence of incomplete epidermal differentiation. Hence, Fra-2 appears to be 
necessary for correct terminal epidermal differentiation in vivo. Notably, the proliferation 
status of basal mKCs remained unaffected at E17.5 in Fra-2Δsb and Fra-2Δep mutants 
(Figure 17A, B). Although Fra-2 is also expressed in basal cells, the phenotype of Fra-2Δsb 
mutants suggests that Fra-2 mainly functions in the differentiated compartment of the 
epidermis. 
 
 
Figure 17. Loss of epidermal Fra-2 does not affect mKC proliferation. (A) Basal cell marker 
expression (K5, green) and proliferation marker expression (Ki67, red) in Co, Fra-2Δsb and Fra-2Δep 
embryos at E17.5; n=5/genotype; 20x magnification. (B) Quantification of Figure 17A, K5+/Ki67+ 
cells/20x field; n=10 fields/genotype; bars represent mean ±SD. 
 
1.12. Cell autonomous differentiation defect in primary Fra-2-deficient mKCs 
The expression of EDC genes was next investigated in primary Fra-2-deficient mKCs in 
vitro. For this purpose, primary mKCs carrying Fra-2 loxed alleles (Fra-2f/f) were infected 
with adeno-Cre (AdCre) viruses for in vitro Cre-mediated Fra-2 inactivation and adeno-
GFP (AdGFP) control viruses. Cre-mediated recombination was assessed by measuring 
non-functional Fra-2Δ-GFP fusion gene expression, which is produced upon excision of 
exon 3 of Fra-2 and fusion of exon 2 with a GFP reporter (Eferl et al., 2007) (Figure 18A). 
Notably, upon deletion of Fra-2 in vitro, the EDC genes Flg, Lor and Lce1k were 
significantly reduced in primary mKCs (Figure 18B). These results further confirm that 
Fra-2 is necessary for the correct expression of these EDC genes. 	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Figure 18. Reduced EDC expression in primary Fra-2-deficient mKCs. (A) Fra-2Δ-GFP mRNA 
expression of primary mKCs carrying Fra-2 loxed alleles (Fra-2f/f) infected with adeno-GFP 
(AdGFP) or adeno-Cre (AdCre) viruses. (B) Differential Fra-2 and EDC gene expression of primary 
Fra-2f/f mKCs infected with AdGFP or AdCre; n=3; * p<0.05, bars represent mean ±SD. 
 
To validate our previous findings, Fra-2 WT and Fra-2 K104F as well as Fra-2 
S320A/T322A mutants were expressed lentivirally as described above in primary Fra-2-
deficient mKCs and the expression of EDC genes was analyzed. 
1.13. Expression of a Fra-2 K104F mutant does not rescue reduced EDC gene 
expression in Fra-2-deficient mKCs 
First, the effect of Fra-2 K104F expression on EDC gene expression in Fra-2-deficient 
mKCs compared to Fra-2 WT expression was evaluated. Cre-mediated recombination was 
assessed by measuring non-functional Fra-2Δ-GFP fusion gene expression (Figures 
19A). Efficient Fra-2 WT and Fra-2 K104F expression was assessed by exogenous Fra-2 
Flag and total Fra-2 expression in these cells (Figures 19B,C). While lentiviral expression 
of Fra-2 WT restored the differentiation defect of primary Fra-2-deficient mKCs, the 
expression of the Fra-2 K104F mutant did not (Figure 19C). These results further confirm 
that lysine methylation of K104 decreases the transcriptional activity of Fra-2 on EDC 
genes in primary mKCs and thus the expression of a lysine-methylation-mimicking mutant 
does not rescue cell autonomous differentiation defects in Fra-2-deficient mKCs.  	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Figure 19. Expression of a Fra-2 K104F mutant does not rescue reduced EDC gene 
expression in Fra-2-deficient mKCs. (A) Fra-2Δ-GFP mRNA expression of primary Fra-2f/f mKCs 
infected with AdGFP or AdCre viruses, expressing Fra-2 WT or Fra-2 K104F mutant compared to 
empty vector infected cells; n=3. (B) Exogenous Fra-2-Flag mRNA expression of primary Fra-2f/f 
mKCs infected with AdGFP or AdCre, expressing Fra-2 WT or Fra-2 K104F mutant compared to 
empty vector infected cells; n=3. (C) Differential Fra-2 and EDC gene expression of primary Fra-2f/f 
mKCs infected with AdGFP or AdCre, expressing Fra-2 WT or Fra-2 K104F compared to empty 
vector infected cells; n=3; bars represent mean ±SD. 
1.14. Expression of a Fra-2 S320A/T322A mutant does not rescue reduced EDC 
gene expression in Fra-2-deficient mKCs  
Next, the effect of Fra-2 S320A/T322A expression on EDC gene expression in Fra-2-
deficient mKCs compared to Fra-2 WT expression was evaluated. Cre-mediated 
recombination was assessed by measuring non-functional Fra-2Δ-GFP fusion gene 
expression (Figures 20A). Efficient Fra-2 WT and Fra-2 S320A/T322A expression was 
assessed by exogenous Fra-2 Flag and total Fra-2 expression in these cells (Figures 
20B,C). While lentiviral expression of Fra-2 WT restored the differentiation defect of 
primary Fra-2-deficient mKCs, the expression of the Fra-2 S320A/T322A mutant did not 
(Figure 20C). These findings confirm that the ability of Fra-2 to induce EDC gene 
expression is reduced upon mutation of C-terminal phospho-acceptor sites and thus the 
expression of a phospho-deficient mutant does not rescue cell autonomous differentiation 
defects in Fra-2-deficient mKCs. 
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Figure 20. Expression of a Fra-2 S320A/T322A mutant does not rescue reduced EDC 
expression in Fra-2-deficient mKCs. (A) Fra-2Δ-GFP mRNA expression of primary Fra-2f/f mKCs 
infected with AdGFP or AdCre viruses, expressing Fra-2 WT or Fra-2 S320A/T322A mutant 
compared to empty vector infected cells; n=3. (B) Exogenous Fra-2-Flag mRNA expression of 
primary Fra-2f/f mKCs infected with AdGFP or AdCre, expressing Fra-2 WT or Fra-2 S320A/T322A 
mutant compared to empty vector infected cells; n=3. (C) Differential Fra-2 and EDC gene 
expression of primary Fra-2f/f mKCs infected with AdGFP or AdCre, expressing Fra-2 WT or Fra-2 
S320A/T322A compared to empty vector infected cells; n=3; bars represent mean ±SD. 
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2. Loss of Fra-2 expression results in skin inflammation 
2.1. Epidermal hyperplasia and inflammation upon loss of epidermal Fra-2 
Altered epidermal differentiation characterizes a multitude of skin diseases. I next 
investigated how the differentiation defects in Fra-2 loss-of-function (LOF) mutants affect 
skin homeostasis. Efficient deletion of Fra-2 in differentiated mKCs (Fra-2Δsb) or all mKCs 
(Fra-2Δep) was evaluated by Fra-2 IHC (Figure 21A). Interestingly, both Fra-2Δsb and Fra-
2Δep mutants displayed striking skin abnormalities at postnatal day 6 (P6) characterized by 
a thinner dermal layer marked by aberrant hair follicle development (Figure 21B; 
quantified in Figure 21C) and epidermal hyperplasia with significantly increased 
epidermal thickness (Figure 21D; quantified in Figure 21E).  
 
 
 
Figure 21. Loss of epidermal Fra-2 results in skin alterations. (A) Fra-2 IHC, H&E analyses to 
evaluate total skin thickness (B,C) and epidermal thickness (D,E) of Co, Fra-2Δsb and Fra-2Δep pups 
at postnatal day (P6); n=8/genotype; * p<0.05, bars represent mean ±SD. 
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While no difference of mKC proliferation was observed during embryonic development, 
IHC analyses showed that the epidermal phenotype of Fra-2 LOF mutants at P6 was 
marked by keratinocyte hyperproliferation, depicted by increased numbers of Ki67 positive 
keratinocytes (Figure 22A; quantified in Figure 22B). Further, increased numbers of 
CD45 positive inflammatory infiltrates predominantly in the upper dermis were found in 
Fra-2 LOF mutants (Figure 22C; quantified in Figure 22D). 
 
 
Figure 22. Loss of epidermal Fra-2 results in keratinocyte hyperproliferation and skin 
inflammation. (A) Ki67 IHC, (B) quantification of Ki67 positive cells, (C) CD45 IHC, (D) 
quantification of CD45 positive cells of Co, Fra-2Δsb and Fra-2Δep pups at P6; n=6/genotype; * 
p<0.05, bars represent mean ±SD. 
 
Besides the inflammatory skin phenotype, Fra-2 LOF mutants were severely growth 
retarded and cachectic at P6, presented less than 50% of the body weight of littermate 
controls (Figure 23A) and died within the first two weeks after birth with complete 
penetrance. Notably, upon loss of epidermal Fra-2, a systemic inflammatory response 
characterized by increased levels of the cytokines TNFα, IL-6, IL-17A, G-CSF, IL-1α and 
TSLP in sera was observed (Figure 23B). Remarkably, loss of Fra-2 in differentiated 
mKCs (Fra-2Δsb) was sufficient to cause this phenotype. Collectively, these findings show 
that besides epidermal differentiation defects, loss of epidermal Fra-2 results in skin and 
systemic inflammation.  
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Figure 23. Loss of epidermal Fra-2 results in systemic inflammation. (A) Body weight analysis 
and (B) serum cytokine analysis of Co, Fra-2Δsb and Fra-2Δep pups at P6; n=8/genotype; * p<0.05, 
bars represent mean ±SD.	  	  
2.2. Soluble factors associated with inflammation are expressed in epidermal 
cells upon loss of Fra-2 
Next, I addressed the mechanisms by which loss of Fra-2 in epithelial cells causes a 
systemic phenotype and which keratinocyte-derived factors are involved in this 
inflammatory response.  
Upon loss of Fra-2 in mKCs the expression of soluble, inflammation-associated factors by 
epidermal cells such as Lipocalin-2 (Lcn2), the S100 genes S100A8, S100A9 as well as 
the cytokine Thymic Stromal Lymphopoietin (TSLP), a marker of skin barrier defects, was 
massively increased (Figure 24). Interestingly, it was previously shown that these 
chemokines and cytokines are causally involved in the development and progression of 
inflammatory skin conditions (Demehri et al., 2008; Dumortier et al., 2010; Schonthaler et 
al., 2014). Additionally, it was suggested that these factors are regulated by NF-κB/p65 
(Lee and Ziegler, 2007; Nemeth et al., 2009; Zhao and Stephens, 2013).  
 
 
 
 
 
 
 
 
 
Results 
	   	   	   87	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Secretion of inflammation-associated factors by epidermal cells upon loss of Fra-
2. Differential Fra-2, Lipocalin 2 (Lcn2), S100A8, S100A9 and Thymic Stromal Lymphopoietin 
(TSLP) gene expression in Fra-2Δsb and Fra-2Δep mutants compared to control littermates at P6; 
n=6/genotype; * p<0.05, bars represent mean ±SD. 
 
2.3. Cell autonomous activation of p65 in Fra-2-deficient mKCs 
Since increased expression of p65 targets was detected upon loss of Fra-2 in epidermal 
keratinocytes, the activity of this TF was evaluated. Notably, increased p65 TF activity was 
measured in epidermal nuclear lysates upon loss of Fra-2 using a DNA-binding ELISA kit 
(Figure 25A). This finding was confirmed in primary Fra-2f/f mKCs. Upon AdCre-mediated 
ex vivo deletion of Fra-2, increased p65 TF activity was detected compared to AdGFP 
infected primary mKCs (Figure 25B). 
 	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Increased p65 activity in the absence of Fra-2. p65 transcription factor activity 
measured in epidermal lysates obtained from Co and Fra-2Δep pups at P6; n=6/genotype (A) and 
primary Fra-2f/f mKCs infected with AdGFP and AdCre in vitro; n=4/genotype (B); * p<0.05, bars 
represent mean ±SD. 
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2.4. Skin phenotype and inflammation are ameliorated in Fra-2/p65Δep DKO 
mutants 
To evaluate the contribution of increased p65 activity in epidermal cells of Fra-2Δep 
mutants, Fra-2/p65Δep double-knock-out (DKO) mutants were generated. Efficient deletion 
of epidermal Fra-2 and p65 was confirmed by IHC (Figure 26A,B). 
 
Figure 26. Loss of epidermal p65 ameliorates the skin phenotype of Fra-2Δep mutants. (A) 
Fra-2 IHC, (B) p65 IHC and H&E analyses to evaluate total skin thickness (C,D) and epidermal 
thickness (E,F) of Co, Fra-2Δep and Fra-2/p65Δep DKO pups at postnatal day (P6); n=8/genotype; * 
p<0.05, bars represent mean ±SD. 
 
Remarkably, the skin phenotype was ameliorated in DKO mutants. The thickness of the 
dermal layer was recovered in Fra-2/p65Δep mutants and hair follicle formation was 
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comparable to control littermates (Figure 26C; quantified in Figure 26D). However, as 
observed in Fra-2Δep mutants, Fra-2/p65Δep DKO mutants still presented epidermal 
hyperplasia with increased epidermal thickness (Figure 26E; quantified in Figure 26F). 
IHC analyses showed that the epidermal hyperplasia of DKO mutants was marked by 
keratinocyte hyperproliferation, depicted by increased numbers of Ki67 positive 
keratinocytes (Figure 27A; quantified in Figure 27B), and increased numbers of CD45 
positive inflammatory infiltrates predominantly in the upper dermis, comparable to Fra-2Δep 
mutants (Figure 27C; quantified in Figure 27D). 
 
Figure 27. Keratinocyte hyperproliferation and skin inflammation is not rescued in Fra-
2/p65Δep DKO mutants. (A) Ki67 IHC, (B) quantification of Ki67 positive cells, (C) CD45 IHC, (D) 
quantification of CD45 positive cells of Co, Fra-2Δep and Fra-2/p65Δep DKO pups at P6; 
n=6/genotype; * p<0.05, bars represent mean ±SD. 
 
Even though the skin phenotype of Fra-2/p65Δep DKO mutants was only partially improved, 
the systemic response was greatly improved with a significant increase in body weight 
from 50 to 80% of control littermates (Figure 28A). Additionally, the serum levels of the 
cytokines IL-6, IL-17A and G-CSF were restored to the levels of littermate controls, the 
levels of TNFα were partially restored, while the levels of IL-1α and TSLP remained 
significantly elevated (Figure 28B). 
In summary, these genetic experiments demonstrate that skin and systemic inflammation 
in Fra-2Δep mutants are partially regulated by NF-κB/p65 activation in mKCs. Even though 
the epidermal hyperplasia was not restored in Fra-2/p65Δep mutants, the amelioration of 
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the systemic inflammation marked by reduced levels of several serum cytokines 
suggested that p65 in mKCs co-regulates the expression of soluble factors.  
 
 
Figure 28. Systemic inflammation ameliorated in Fra-2/p65Δep DKO mutants. (A) Body weight 
analysis and (B) serum cytokine analysis of Co, Fra-2Δep and Fra-2/p65Δep DKO pups at P6; 
n=8/genotype; * p<0.05, bars represent mean ±SD.	  	  
2.5. Expression of NF-κB-dependent and independent soluble factors by 
epidermal cells upon loss of Fra-2 
Since the mentioned soluble factors expressed upon loss of epidermal Fra-2 have been 
linked to NF-κB signaling, their expression was evaluated in epidermal samples of Fra-
2/p65Δep DKO mutants. Notably, the expression of Lcn2, S100A8 and S100A9 was 
significantly reduced compared to Fra-2Δep mutants but still increased compared to control 
littermates. However, TSLP expression was not reduced compared to Fra-2Δep mutants 
(Figure 29A). These findings show that increased p65 activity contributes to the increased 
expression of Lcn2, S100A8 and S100A9 upon loss of Fra-2. This might explain the 
amelioration of the systemic inflammatory response observed in Fra-2/p65Δep DKO 
mutants. Surprisingly and in contrast to what has been suggested in published reports 
(Lee et al., 2008; Lee and Ziegler, 2007), the expression of TSLP by epidermal cells was 
NF-κB/p65-independent, which was confirmed at the protein level by ELISA (Figure 29B). 
These experiments suggest an important function of p65 in Fra-2-deficient mKCs. 
Inflammation-associated factors expressed by keratinocytes might activate different 
subsets of immune cells to secrete additional inflammatory mediators. Collectively, 
reduced expression of some chemokines and cytokines by epidermal cells of Fra-2/p65Δep 
DKO mutants might result in reduced serum cytokines produced by immune cells and 
hence reduced systemic inflammation. 
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Figure 29. Secretion of inflammation-associated factors partially restored in Fra-2/p65Δep 
DKO mutants. (A) Differential Fra-2, p65, Lcn2, S100A8, S100A9 and TSLP gene expression and 
(B) TSLP protein expression in Fra-2Δep and Fra-2/p65Δep DKO mutants compared to control 
littermates at P6; n=6/genotype; * p<0.05, bars represent mean ±SD. 
2.6. Fra-2 indirectly regulates epithelial-derived TSLP expression 
TSLP was consistently up-regulated in Fra-2Δep mutants and found independently 
regulated by NF-κB/p65. We next evaluated TSLP expression upon loss of/increased Fra-
2 expression in primary mKCs in vitro to assess its cell-autonomous regulation by Fra-2. 
As shown previously, Fra-2 expression correlated with the expression of the terminal 
differentiation gene Flg. Surprisingly, an inverse correlation of Fra-2 and TSLP expression 
in primary mKCs was found: TSLP expression by mKCs upon loss of Fra-2 was increased 
while it was blocked upon increased Fra-2 expression (Figure 30A,B). Interestingly, ChIP 
experiments failed to detect binding of Fra-2 to an AP-1 consensus site in the TSLP 
promoter (Figure 30C). These findings indicate that even though the expression of TSLP 
is modulated cell autonomously by Fra-2, it is likely not regulated by direct binding of Fra-2 
to the TSLP promoter. In summary, these experiments suggest that the expression of 
TSLP is inversely correlated with the differentiation status of primary mKCs. 
 
Figrue 30. TSLP expression is indirectly regulated by Fra-2 in primary mKCs. (A,B) 
Differential Fra-2, TSLP and Flg expression in primary Fra-2-deficient (A) and Fra-2Ep-tetOFF mKCs 
(B) compared to control cells. (C) ChIP analysis of Fra-2 binding to an AP-1 consensus site in the 
TSLP promoter; n=4; * p<0.05, bars represent mean ±SD. 
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2.7. Transplantation of Fra-2Δep skin to immune-deficient mice results in the 
formation of skin tumors 
As Fra-2Δep mutants died within 2 weeks after birth, skin transplantation assays were 
performed to monitor the progression of the inflammatory skin phenotype. Skin of control 
as well as Fra-2Δep pups at P2 was grafted onto immune-compromised SCID (severe 
combined immunodeficiency) mice and analyzed after 4 weeks. Interestingly, Fra-2-
deficient skin grafts gave rise to skin papillomas in the absence of functional B and T cells 
(Figure 31A). The lesions of Fra-2Δep grafts presented epidermal hyperplasia, hyper- and 
parakeratosis and atypia 4 weeks after transplantation (Figure 31B). The transplanted 
skin of Fra-2Δep mutants was highly proliferative (Figure 31C) and presented massive 
infiltration of CD45 positive immune cells (Figure 31D). We hypothesize that the absence 
of T cells might be the cause of skin papilloma formation in Fra-2Δep grafts since it has 
been demonstrated that T cells, activated by TSLP, cause a tumor protective 
microenvironment (Demehri et al., 2012; Di Piazza et al., 2012). These findings are of high 
relevance because the blockade of TSLP has been suggested to be a promising 
therapeutic strategy to treat AD patients. 
 
 
 
Figure 31. Fra-2Δep skin grafts give rise to papillomas. (A) Macroscopic appearance, (B) 
microscopic appearance, (C) Ki67 IHC and (D) CD45 IHC of Co and Fra-2Δep skin grafts 4 weeks 
after transplantation; n=6/genotype.  
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In this thesis I describe how the AP-1 transcription factor Fra-2 controls epidermal barrier 
homeostasis by a dual mechanism: First, I demonstrate that Fra-2 regulates the 
expression of epidermal differentiation genes upon interaction with Ezh2 and ERK1/2. 
Second, I show that this mechanism is essential and that the absence of Fra-2 in 
epidermal keratinocytes causes an inflammatory skin phenotype characterized by the 
secretion of cytokines and chemokines by keratinocytes and the activation of NF-κB. 
 
1.1. Functions of Fra-2 during keratinocyte differentiation 
In the first part of this study, I have identified Fra-2 as a novel Ezh2 substrate in basal cells 
of the epidermis, which acts as a key regulator of terminal epidermal differentiation. 
Mechanistically, Fra-2 binds conserved AP-1 consensus sites in EDC promoters and 
induces transcriptional activation, when phosphorylated by ERK1/2. Unlike other master 
regulators of terminal epidermal differentiation such as Klf4, which is expressed 
suprabasally (Segre et al., 1999), Fra-2 is expressed and bound at EDC promoters in 
basal and differentiated keratinocytes. In basal cells, Fra-2 is unphosphorylated, 
methylated on K104 and transcriptionally inactive. Using genetic loss of function 
approaches in mice, we demonstrate that loss of Fra-2 in suprabasal cells is sufficient to 
cause skin barrier defects. These data support the observation that even though 
expressed in all epidermal keratinocytes, Fra-2 is only active and mainly functions in the 
differentiated layers of the epidermis. Conversely, we show that ectopic Fra-2 expression 
is sufficient to induce terminal epidermal differentiation leading to suppression of papilloma 
growth by inducing precocious keratinocyte differentiation.  
 
1.2. Fra-2 is kept transcriptionally inactive by methylation 
Given our in vitro and in vivo data, I speculate that Fra-2 is kept transcriptionally inactive in 
basal cells due to methylation by Ezh2. Upon Ca2+-induced differentiation, the concomitant 
loss of interaction with Ezh2, loss of Fra-2 methylation and ERK1/2-mediated 
phosphorylation correlates with EDC gene expression and keratinocyte differentiation. 
Using Ca2+ treatment to induce keratinocyte differentiation, I demonstrate that basal 
keratinocytes differentiate prematurely upon inhibition of Ezh2. These findings are in 
agreement with published results of in vivo gene targeting of Ezh2 in the epidermis. Ezh2-
null keratinocytes differentiate prematurely and express higher levels of EDC genes with 
increased AP-1 transcription factor activity (Ezhkova et al., 2009). It was previously shown 
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that Ezh2 can modify the activity of some transcription factors through methylation (He et 
al., 2012; Kim et al., 2013; Lee et al., 2012; Xu et al., 2012). Employing MS-based 
approaches, we identified mono- and dimethylation on K104 of Fra-2 in basal mKCs. To 
our knowledge, this is the first work showing methylation of an AP-1 transcription factor. 
Additionally, I demonstrate by lentiviral expression of a Fra-2 mutant mimicking lysine 
methylation that this modification decreases the transcriptional activity of Fra-2 on EDC 
genes. Interestingly, K104 of Fra-2 was found acetylated in an independent study (Park et 
al., 2013), suggesting a potential role of this residue in regulating the transcriptional 
activity of this protein. We hypothesize that Fra-2 K104 methylation influences the 
interaction of Fra-2 with transcriptional co-activators, as it has been described for 
methylated GATA4 (He et al., 2012). 
During the last decade several independent studies established that Ezh2 is 
overexpressed in solid tumors, and is associated with aggressive cancers and progression 
(Hock, 2012). In human cancers, whether H3K27 methylation is the only way by which 
Ezh2 controls tumorigenesis remains unclear. Since Ezh2 has other substrates beyond 
histone H3, it was proposed that Ezh2 might facilitate tumorigenesis by regulating the 
activity of non-histone substrates such as transcription factors (He et al., 2012; Kim et al., 
2013). Interestingly, skin papillomas of poorly differentiated K5-SOS-F mice show high 
levels of Ezh2 and express Fra-2. Importantly, ectopic expression of Fra-2 in this 
background resulted in reduced papilloma growth due to precocious differentiation. These 
findings suggest that the ratio of expression of Ezh2 to its substrates, among them Fra-2, 
is crucial in regulating epidermal differentiation and tumorigenesis. Further research will be 
necessary to assess the expression of Ezh2 and Fra-2 in human skin diseases 
characterized by epidermal differentiation defects, in order to evaluate the possible clinical 
benefit of blocking Ezh2 as a therapeutic strategy.  
 
1.3. Increased transcriptional activity of Fra-2 upon C-terminal phosphorylation 
Additionally, we identify an important function of the MAP kinases ERK1/2 in terminal mKC 
differentiation by phosphorylating and stabilizing Fra-2. ERK1/2 are activated upon Ca2+-
induced differentiation via PKCα and the inhibition of ERK1/2 results in reduced 
expression of terminal keratinocyte differentiation genes (Schmidt et al., 2000; Seo, 2004). 
I provide further mechanistic insights demonstrating that Fra-2 is phosphorylated by 
ERK1/2 and acts as an ERK1/2-dependent inducer of terminal differentiation by regulating 
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EDC gene expression. Additionally, in vivo analyses of ERK1/2 phosphorylation in 
developing embryos showed a clear nuclear pattern in suprabasal cells indicating 
essential functions of activated ERK1/2 in epidermal barrier acquisition. Previously 
published studies revealed that ERK2 phosphorylates Fra-2 on 5 serine and threonine 
residues in vitro (Alli et al., 2013). Targeted mutagenesis of these residues demonstrated 
that the C-terminal phosphorylation of Fra-2 on serine 320 and threonine 322 results in 
increased protein stability (Alli et al., 2013). Using an antibody against phospho serine 
320, which is conserved among Fra-1, Fra-2 and c-Fos, we found that C-terminal Fra-2 
phosphorylation is increased upon mKC differentiation correlating with ERK1/2 activation 
and Fra-2 transcriptional activity at EDC target genes. In addition, I functionally validated 
the role of C-terminal Fra-2 phosphorylation in primary mKCs by expression of phospho-
deficient Fra-2 mutants, which exhibited reduced transcriptional activity. 
I propose a novel mechanism how Fra-2/AP-1 activity is regulated through lysine 
methylation by Ezh2 and C-terminal serine phosphorylation by ERK1/2 in mKCs. It will be 
interesting to explore in future studies whether this methyl-phospho switch is a general 
mechanism of transcription factor regulation and to study the possible implications in skin 
diseases and beyond. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-D. Proposed model of transcriptional regulation of EDC genes by Fra-2, Ezh2 and 
ERK1/2. 
1.4. Fra-2 expression in suprabasal cells is necessary for skin barrier acquisition  
Using LOF and GOF approaches in mouse models and primary keratinocyte cultures, I 
have identified Fra-2 as a key activator of terminal keratinocyte differentiation. The finding 
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that loss of Fra-2 specifically in differentiated keratinocytes gives rise to epidermal barrier 
defects, similar to those observed when Fra-2 is deleted in both basal and differentiated 
keratinocytes, supports the conclusion that epidermal Fra-2 is an essential regulator of 
terminal keratinocyte differentiation. Reduced expression of epidermal differentiation 
genes such as Flg upon Fra-2 loss is likely responsible for the barrier defect. Using a 
mouse model that lacks processed murine Flg due to a frameshift mutation in the gene 
encoding profilaggrin, which mimics mutations found in 9% of human AD cases, it was 
demonstrated that Flg deficiency alone decreases stratum corneum hydration and leads to 
skin barrier abnormalities (Scharschmidt et al., 2009). However, in around two thirds of AD 
patients with skin barrier deficiencies, Flg is properly expressed (Jakasa et al., 2011). This 
points to the existence of different subtypes of AD in humans that might be caused due to 
reduced expression of other epidermal differentiation genes, or deregulated expression of 
upstream regulators such as transcription factors. 
 
2.1. Loss of epidermal Fra-2 – a mouse model to study inflammatory skin 
diseases 
In human skin diseases, a defect in the tightly orchestrated, stepwise process of epidermal 
differentiation has been associated with epidermal hyperplasia and skin inflammation. 
Previous studies have established that keratinocyte hyperproliferation is a compensatory 
response and secondary to epidermal barrier defects (Matsuki et al., 1998; Proksch et al., 
1991; Segre et al., 1999) and that the activation of inflammation-associated signaling 
pathways, such as NF-κB are crucially involved in the initiation of skin inflammation. 
Besides epidermal barrier defects, mutant mice with epithelial-specific deletion of Fra-2 
exhibit skin lesions with clinical features reminiscent to the ones observed in patients with 
AD or psoriasis. First, Fra-2 LOF mutants exhibit epidermal hyperplasia characterized by 
increased epidermal proliferation, as observed in AD and psoriasis patients (Proksch et 
al., 2008; Wagner et al., 2010). Second, Fra-2-deficient keratinocytes show dramatically 
increased expression of the Th2-type cytokine TSLP, which is crucially involved in the 
initiation of AD (Ziegler and Artis, 2010) as well as increased expression of the 
chemokines S100A8, S100A9 and Lcn2, which have been linked to the pathogenesis of 
psoriasis (Kamata et al., 2012; Schonthaler et al., 2014). Third, activation of NF-κB was 
found in these mutant mice. The activation and nuclear translocation of NF-κB is often 
associated with increased epidermal proliferation and is considered a critical event in the 
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progression and maintenance of AD as well as psoriasis (Dajee et al., 2006; Lizzul et al., 
2005). Importantly, loss of suprabasal Fra-2 is sufficient to cause these phenotypic 
features. Taking these findings together, I propose that mouse models with epidermal Fra-
2 deletion may serve as useful tools to study the pathology of inflammatory skin diseases 
such as AD and psoriasis.  
 
2.2. Expression of soluble factors in mKCs upon loss of epidermal Fra-2 
Epidermal keratinocytes are key initiators of immune responses through the secretion of 
soluble factors that induce immune cell activation and thereby adaptive immune responses 
(Holgate, 2007). In this study, increased expression of the NF-κB/p65 targets S100A8/A9, 
Lcn2 and TSLP by epidermal cells is found upon loss of Fra-2. Previous studies 
established that the expression of these soluble factors is linked to skin barrier defects and 
that increased expression of TSLP is sufficient to initiate skin inflammation (Demehri et al., 
2008; Kamata et al., 2012; Yoo et al., 2005; Zenz et al., 2005). Additionally, increased p65 
activity is detected in Fra-2-deficient keratinocytes. Employing Fra-2/p65Δep DKO mutant 
mice, we genetically demonstrate that the absence of p65 results in reduced expression of 
S100A8/A9 and Lcn2 and thereby validate that p65 contributes to regulate their 
expression. Since S100A8/A9 and Lcn2 affect the activity of various immune cells, 
reduced expression of these soluble factors by mKCs might explain the amelioration of the 
systemic inflammatory response, assessed by reduced levels of the 
inflammatory/hematopoietic cytokines IL-6, IL-17 and G-CSF in sera of Fra-2/p65Δep DKO 
mutants. Reduced levels of these cytokines may also explain the improved body weight of 
Fra-2/p65Δep DKO mutant mice compared to Fra-2Δep mutant mice. However, high serum 
levels of IL-1α, TNFα and TSLP were still measured also in the absence of p65 in Fra-
2/p65Δep DKO mutants. These results demonstrate that upon loss of Fra-2, p65/NF-κB in 
keratinocytes is involved in initiating inflammation, but that loss of Fra-2 affects the 
expression of specific cytokines in a p65-independent manner.  
 
2.3. Epidermal p65 does not regulate epidermal hyperplasia and skin 
inflammation upon skin barrier defects 
The use of mice lacking IκBα, the main inhibitory protein that controls NF-κB activation, 
has shown that increased NF-κB activation triggers increased keratinocyte proliferation, 
epidermal hyperplasia and immune cell infiltration in the dermis and in the epidermis 
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(Klement et al., 1996). While the differentiation status of epidermal keratinocytes remained 
unaffected upon loss of p65, epidermal p65 was found to be essential for DMBA-/TPA-
induced skin carcinogenesis. Moreover, keratinocyte-specific p65 deficiency prevents 
TPA-induced epidermal hyperproliferaiton and the expression of inflammatory cytokines 
and chemokines by keratinocytes (Kim and Pasparakis, 2014). Even though Fra-2/p65Δep 
DKO mice show striking microscopic improvements in skin architecture, as judged by total 
skin thickness and hair follicle formation, epidermal hyperplasia is not rescued. These 
findings suggest that keratinocyte hyperproliferation in this model is not regulated by 
epidermal p65, but likely triggered by epidermal differentiation defects,. 
Notably, as observed in Fra-2Δep mutants, the skin of Fra-2/p65Δep DKO mutants exhibits 
massive infiltration of CD45 positive immune cells, indicating that p65 activity is not 
necessary for the recruitment of inflammatory cells. Since this finding is contradictory to 
the result that Fra-2/p65Δep DKO mutant mice show reduced levels of several 
inflammatory/hematopoietic cytokines in the serum, it would be interesting to analyze in 
detail the subtypes of immune cells present in Fra-2Δep and Fra-2/p65Δep DKO skin. 
Moreover, I suggest measuring the secretion of cytokines to evaluate whether different 
populations are involved in the skin inflammatory response in Fra-2/p65Δep DKO mice. The 
findings that epidermal hyperplasia and skin inflammation are still present upon removal of 
p65 suggest that these features might be secondary to epidermal differentiation defects 
upon loss of Fra-2 and are not directly linked to p65 activity. For all these reasons, the 
inhibition of p65 might not be a valuable therapeutic strategy for inflammatory skin 
diseases characterized by altered epidermal differentiation. The deletion of p65 in mKCs 
of Fra-2Δep mutants, a mouse model of skin inflammation characterized by skin barrier 
defects, only partially ameliorates the systemic inflammatory response, likely due to 
reduced expression of keratinocyte-derived chemokines, while epidermal hyperplasia and 
skin inflammation remain unaffected. 
 
2.4. Indirect regulation of TSLP by Fra-2 
The expression of the cytokine TSLP by keratinocytes was initially suggested to be a 
consequence of skin barrier defects as observed in a mouse model upon loss of Notch 
signaling in the developing epidermis (Demehri et al., 2008) and was linked to NF-κB 
pathway activation (Briot et al., 2009; Dumortier et al., 2010). TSLP, a Th2 cytokine, has 
been studied intensively in the pathogenesis of allergic inflammation and subsequent 
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development of AD and other immune disorders (Liu, 2006; Soumelis et al., 2002; Yoo et 
al., 2005). The role of TSLP in AD skin lesions is to promote the recruitment, proliferation 
and maturation of Th2 immune cells to the lesional site. Here I show that TSLP expression 
is regulated cell autonomously upon loss or increased expression of Fra-2 in 
keratinocytes. Fra-2 ChIP experiments and the analyses of Fra-2/p65Δep DKO mice seem 
to exclude a direct transcriptional regulation of Fra-2 and p65 on the TSLP promoter, even 
though several reports suggest a transcriptional function of AP-1 and NF-κB TFs on the 
transcriptional regulation of TSLP (Dumortier et al., 2010; Lee et al., 2008; Redhu et al., 
2011). More extensive analyses, in particular binding of other members of the AP-1 and 
NF-κB TF family to the TSLP promoter will be required to understand the transcriptional 
regulation of this gene.  
 
2.5. Expression of TSLP inversely correlated with the differentiation status of 
mKCs 
Even though our studies highlight a cell autonomous regulation of TSLP expression that is 
inversely correlated with the expression of Fra-2 and the differentiation status of mKCs, 
the transcriptional regulation of TSLP upon keratinocyte differentiation defects remains 
largely unknown. 
Interestingly, one recent study linked TSLP expression to an increase in intracellular Ca2+ 
levels and the activation of NFAT transcription factors (Wilson et al., 2013). Given the fact 
that a calcium gradient is required for efficient mKC differentiation in vitro and in vivo 
(Menon et al., 1985) and that this calcium gradient is lost in inflammatory skin disorders 
(Menon et al., 1992), the question arises whether incomplete mKC differentiation results in 
altered intracellular calcium levels and subsequent changes in the activity of calcium-
sensing TFs, such as members of the NFAT family. Hypothetically, if a differentiation 
defect results in an increase of intracellular calcium levels, this might activate calcium-
binding proteins such as the S100 chemoattractants, which are causally involved in the 
pathogenesis of inflammatory skin diseases. Additionally, the concept of differentiation-
regulated calcium levels might explain reduced TSLP expression upon increased 
expression of EDC genes in mKCs ectopically expressing Fra-2. Therefore, I plan to 
measure intracellular calcium levels, the activity of NFAT transcription factors and the 
expression of calcineurin, the phosphatase that activates NFAT TFs (Loh et al., 1996), 
upon loss and increased expression of Fra-2 in mKCs. If the hypothesis holds true that the 
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expression of TSLP is regulated by calcium levels, which depend on the differentiation 
status of keratinocytes, this cytokine would present an important link how skin barrier 
defects cause skin inflammation.  
2.6. Fra-2 – p65 interaction: competition for co-activators? 
The question how p65 is activated in the absence of Fra-2 remains to be answered. Early 
studies suggest an interaction of AP-1 and NF-κB TFs via the co-activator p300 or its 
homolog CBP (Gerritsen et al., 1997; Torchia et al., 1998). In these reports, the concept of 
competition of AP-1 and NF-κB TFs for interaction with p300/CBP was proposed 
(Sheppard et al., 1998). Interestingly, the acetylation of p65 by the acetyltransferases 
p300/CBP on lysine 310 has been linked to increased transcriptional activity (Chen et al., 
2002). In future studies I plan to evaluate whether the interaction with p300 and the 
acetylation of p65 on lysine 310 is increased in mKCs upon loss of Fra-2 by the use of 
coIP experiments, MS and Western blot analyses. The hypothesis is that upon loss of Fra-
2, p65 can interact more easily with the transcriptional co-activators and 
acetyltransferases p300/CBP, increasing its transcriptional activity and thereby inducing 
the expression of its target genes. 
 
2.7. Linking altered epidermal differentiation, skin inflammation and skin cancer 
I have shown in this thesis that the AP-1 transcription factor Fra-2 regulates epidermal 
barrier immunity at two levels: by transcriptionally activating the expression of epithelial 
differentiation genes and by keeping inflammatory mediators, such as the TF p65 and 
inflammation-associated soluble factors, under control. 
While most of these results were obtained from studying Fra-2 LOF mouse models, some 
of these findings were confirmed using an epithelial-specific Fra-2 GOF mouse model. We 
found that keratinocytes differentiated prematurely and the expression of TSLP was 
blocked upon exogenous Fra-2 expression. Additionally, I have shown a functional 
relevance of ectopic Fra-2 expression in vivo in a papilloma-prone mouse model, which 
presents skin barrier defects. K5-SOS-F transgenic mice that ectopically express Fra-2 
show smaller lesions, which are more differentiated. These findings indicate important 
functions of Fra-2 and the expression of terminal differentiation genes in skin tumors. 
Importantly, transplantation of Fra-2Δep mutant skin to immune-compromised mice, which 
lack functional B and T cells, gave rise to the formation of skin papillomas. A recent 
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concept suggests that TSLP, secreted by keratinocytes upon barrier defects, establishes a 
tumor protective environment by activating T cells (Demehri et al., 2012; Di Piazza et al., 
2012). Along these lines, results from our transplantation model imply that the absence of 
B and T cells in barrier-defective skin may promote the development of skin papillomas 
that might progress to invasive SCCs.  
Additional studies are necessary to understand the two faces of inflammation and tumor 
development in skin. In this thesis, I concentrated on the question of how epidermal 
differentiation defects give rise to skin inflammation. I have shown that the activity of the 
transcription factor Fra-2 is crucial during epidermal development and it is regulated by 
Ezh2- and ERK1/2-dependent posttranslational modifications. Incomplete epidermal 
differentiation results in skin inflammation likely due to cell autonomous activation of NF-
κB and the expression of the cytokine TSLP by keratinocytes. Since proper epidermal 
differentiation and the expression of inflammatory mediators by keratinocytes are crucially 
involved in the initiation of inflammatory skin diseases and skin tumorigenesis, my work 
has provided a basis for future work aiming at preventing, detecting or curing skin 
diseases.  
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1) Fra-2 functions as a key regulator of keratinocyte differentiation by inducing the 
expression of epidermal differentiation genes upon interaction with Ezh2 and ERK1/2. Fra-
2 activity is regulated by lysine methylation in basal keratinocytes and by C-terminal 
phosphorylation upon keratinocyte differentiation.  
 
2) Ectopic Fra-2 expression induces epidermal differentiation in vivo during 
development and suppresses skin papilloma growth due to increased expression of 
epidermal differentiation genes. 
 
3) Fra-2 expression is necessary for proper epidermal differentiation and skin barrier 
acquisition.  
 
4) Loss of epidermal Fra-2 results in inflammation characterized by epidermal 
hyperplasia, infiltration of inflammatory cells into the skin, increased activity of p65 in 
keratinocytes, secretion of inflammation-associated factors by epidermal cells and high 
serum cytokine levels. 
 
5) Concurrent deletion of Fra-2 and p65 results in an amelioration of the systemic 
phenotype, likely due to reduced expression of inflammation-associated soluble factors by 
epidermal cells, but does not rescue keratinocyte hyperproliferation and skin inflammation 
observed upon loss of epidermal Fra-2. 
 
6) Expression of Fra-2 and EDC genes is inversely correlated with TSLP expression; 
however, Fra-2 does not appear to regulate TSLP expression by direct promoter binding. 
 
7) Skin barrier defects upon loss of epidermal Fra-2 in an immune-compromised 
background result in the formation of skin papillomas.  
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1) Fra-2 funciona como un regulador clave de la diferenciación de los queratinocitos 
mediante la inducción de la expresión de genes de diferenciación epidérmica tras la 
interacción controlada con Ezh2 y ERK1/2. La actividad de Fra-2 está regulada por la 
metilación de lisinas en los queratinocitos basales y su fosforilación en posición C-
terminal tras la diferenciación. 
 
2) La expresión ectópica de Fra-2 induce la diferenciación epidérmica in vivo durante 
el desarrollo y suprime el crecimiento de los papilomas de la piel debido a un aumento 
de expresión de genes de diferenciación epidérmica. 
 
3) La expresión de Fra-2 es necesaria para la adecuada diferenciación epidérmica y la 
adquisición de la función barrera de la piel. 
 
4) La pérdida de la expresión de Fra-2 en la epidermis resulta en una inflamación 
caracterizada por hiperplasia epidérmica, infiltración de células inflamatorias en la piel, 
aumento de la actividad de p65 en los queratinocitos, la secreción de factores 
asociados con la inflamación por las células epidérmicas y niveles de citoquinas 
séricas elevadas. 
 
5) La eliminación simultánea de Fra-2 y p65 resulta en una mejora del fenotipo 
sistémico, probablemente debido a la reducción de la expresión de factores solubles 
asociados a la inflamación por las células epidérmicas, pero no anula la 
hiperproliferación de queratinocitos y la inflamación de la piel producida tras la pérdida 
de Fra- 2 en la epidermis. 
 
6) La expresión de Fra-2 y genes EDC está inversamente relacionada con la 
expresión de TSLP, sin embargo, Fra-2 no regula la expresión de TSLP directamente 
mediante la unión a su promotor. 
 
7) Los defectos de la función barrera de la piel producidos por la pérdida de Fra-2 en 
la epidermis, en un modelo inmunodeficiente, dan lugar a la formación de papilomas 
en la piel. 
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